<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Immunoglobulin for alloimmune hemolytic disease in neonates - Zwiers, C - 2018 | Cochrane Library</title> <meta content="Immunoglobulin for alloimmune hemolytic disease in neonates - Zwiers, C - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003313.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Immunoglobulin for alloimmune hemolytic disease in neonates - Zwiers, C - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003313.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003313.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Immunoglobulin for alloimmune hemolytic disease in neonates" name="citation_title"/> <meta content="Carolien Zwiers" name="citation_author"/> <meta content="Leiden University Medical Center" name="citation_author_institution"/> <meta content="Mirjam EA Scheffer‐Rath" name="citation_author"/> <meta content="Leiden University Medical Center" name="citation_author_institution"/> <meta content="Enrico Lopriore" name="citation_author"/> <meta content="Leiden University Medical Center" name="citation_author_institution"/> <meta content="Masja de Haas" name="citation_author"/> <meta content="Helen G Liley" name="citation_author"/> <meta content="Mater Mothers' Hospital, Mater Research, The University of Queensland" name="citation_author_institution"/> <meta content="Helen.Liley@mater.org.au" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD003313.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/03/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003313.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003313.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003313.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anemia, Hemolytic [immunology, *therapy]; Anemia, Neonatal [immunology, *therapy]; Blood Transfusion; *Immunoglobulins, Intravenous; Jaundice, Neonatal [immunology, *therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003313.pub2&amp;doi=10.1002/14651858.CD003313.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="eLIOL3Be";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003313\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003313\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003313\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003313\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003313.pub2",title:"Immunoglobulin for alloimmune hemolytic disease in neonates",firstPublishedDate:"Mar 18, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003313.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003313.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003313.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003313.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003313.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003313.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003313.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003313.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003313.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003313.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10357 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003313.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/full#CD003313-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/full#CD003313-sec-0086"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/full#CD003313-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/full#CD003313-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/full#CD003313-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/full#CD003313-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/full#CD003313-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/full#CD003313-sec-0080"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/appendices#CD003313-sec-0091"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/table_n/CD003313StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/table_n/CD003313StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Immunoglobulin for alloimmune hemolytic disease in neonates</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/information#CD003313-cr-0002">Carolien Zwiers</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/information#CD003313-cr-0003">Mirjam EA Scheffer‐Rath</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/information#CD003313-cr-0004">Enrico Lopriore</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/information#CD003313-cr-0005">Masja de Haas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003313.pub2/information#CD003313-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Helen G Liley</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/information/en#CD003313-sec-0096">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 March 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003313.pub2">https://doi.org/10.1002/14651858.CD003313.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003313-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003313-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003313-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003313-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003313-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003313-abs-0001" lang="en"> <section id="CD003313-sec-0001"> <h3 class="title" id="CD003313-sec-0001">Background</h3> <p>Exchange transfusion and phototherapy have traditionally been used to treat jaundice and avoid the associated neurological complications. Because of the risks and burdens of exchange transfusion, intravenous immunoglobulin (IVIg) has been suggested as an alternative therapy for alloimmune hemolytic disease of the newborn (HDN) to reduce the need for exchange transfusion. </p> </section> <section id="CD003313-sec-0002"> <h3 class="title" id="CD003313-sec-0002">Objectives</h3> <p>To assess the effect and complications of IVIg in newborn infants with alloimmune HDN on the need for and number of exchange transfusions. </p> </section> <section id="CD003313-sec-0003"> <h3 class="title" id="CD003313-sec-0003">Search methods</h3> <p>We performed electronic searches of CENTRAL, PubMed, Embase (Ovid), Web of Science, CINAHL (EBSCOhost), Academic Search Premier, and the trial registers ClinicalTrials.gov and controlled‐trials.com in May 2017. We also searched reference lists of included and excluded trials and relevant reviews for further relevant studies. </p> </section> <section id="CD003313-sec-0004"> <h3 class="title" id="CD003313-sec-0004">Selection criteria</h3> <p>We considered all randomized and quasi‐randomized controlled trials of IVIg in the treatment of alloimmune HDN. Trials must have used predefined criteria for the use of IVIg and exchange transfusion therapy to be included. </p> </section> <section id="CD003313-sec-0005"> <h3 class="title" id="CD003313-sec-0005">Data collection and analysis</h3> <p>We used the standard methods of Cochrane and its Neonatal Review Group. We assessed studies for inclusion and two review authors independently assessed quality and extracted data. We discussed any differences of opinion to reach consensus. We contacted investigators for additional or missing information. We calculated risk ratio (RR), risk difference (RD) and number needed to treat for an additional beneficial outcome (NNTB) for categorical outcomes. We calculated mean difference (MD) for continuous variables. We used GRADE criteria to assess the risk of bias for major outcomes and to summarize the level of evidence. </p> </section> <section id="CD003313-sec-0006"> <h3 class="title" id="CD003313-sec-0006">Main results</h3> <p>Nine studies with 658 infants fulfilled the inclusion criteria. Term and preterm infants with Rh or ABO (or both) incompatibility were included. The use of exchange transfusion decreased significantly in the immunoglobulin treated group (typical RR 0.35, 95% CI 0.25 to 0.49; typical RD ‐0.22, 95% CI ‐0.27 to ‐0.16; NNTB 5). The mean number of exchange transfusions per infant was also significantly lower in the immunoglobulin treated group (MD ‐0.34, 95% CI ‐0.50 to ‐0.17). However, sensitivity analysis by risk of bias showed that in the only two studies in which the treatment was masked by use of a placebo and outcome assessment was blinded, the results differed; there was no difference in the need for exchange transfusions (RR 0.98, 95% CI 0.48 to 1.98) or number of exchange transfusions (MD ‐0.04, 95% CI ‐0.18 to 0.10). Two studies assessed long‐term outcomes and found no cases of kernicterus, deafness or cerebral palsy. </p> </section> <section id="CD003313-sec-0007"> <h3 class="title" id="CD003313-sec-0007">Authors' conclusions</h3> <p>Although overall results show a significant reduction in the need for exchange transfusion in infants treated with IVIg, the applicability of the results is limited because of low to very low quality of evidence. Furthermore, the two studies at lowest risk of bias show no benefit of IVIg in reducing the need for and number of exchange transfusions. Based on these results, we have insufficient confidence in the effect estimate for benefit of IVIg to make even a weak recommendation for the use of IVIg for the treatment of alloimmune HDN. Further studies are needed before the use of IVIg for the treatment of alloimmune HDN can be recommended, and should include blinding of the intervention by use of a placebo as well as sufficient sample size to assess the potential for serious adverse effects. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003313-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003313-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003313-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003313-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003313-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003313-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003313-abs-0003" lang="en"> <h3>Immunoglobulin for alloimmune hemolytic disease in newborns</h3> <p><b>Review question</b> </p> <p>Is IVIg effective in reducing the need for exchange transfusion in newborns with alloimmune hemolytic disease of the newborn (HDN)?<br/> <br/> <b>Background</b> </p> <p>In alloimmune HDN, maternal antibodies (circulating proteins that are produced by the immune system in response to the presence of a foreign substance) are produced against fetal blood cells. These antibodies are transferred across the placenta and destroy red blood cells, leading to fetal anemia (deficiency of red cells in the unborn baby). Intrauterine (within the womb) blood transfusion is used to treat severe fetal anemia. After birth, the antibodies persist in the infant and cause hyperbilirubinemia (a raised blood level of an orange‐yellow pigment (bilirubin, a waste product of a degrading red blood cell) with the risk of serious brain damage (kernicterus) and anemia. Traditional treatment of hyperbilirubinemia consists of (intensive) phototherapy (light treatment) and exchange transfusion (where the baby's blood is replaced with that of a donor; ET). Because ET is an invasive, high risk procedure, alternative treatments such as intravenous immunoglobulin (IVIg), have been investigated. IVIg is thought to reduce the rate of hemolysis and consequently the need for ETs. </p> <p><b>Study characteristics</b> </p> <p>We searched the medical literature to 19 May 2017 and found nine randomized (clinical studies where people are randomly put into one of two or more treatment groups) or partly (quasi) randomized trials (including 658 participants) that assessed the efficiency of IVIg in infants with alloimmune HDN. </p> <p><b>Key results</b> </p> <p>Analysis of all included studies showed a reduction in the need for and number of ETs in infants treated with IVIg combined with phototherapy compared to infants treated with phototherapy only. However, this was not confirmed in an analysis of the two placebo‐controlled studies (where a pretend treatment was given). There was no difference in the need for or number of top‐up transfusions. </p> <p><b>Quality of evidence</b> </p> <p>The evidence from the studies was very low quality. However, two studies used a placebo, thereby minimizing bias and allowing blinding of the researchers assessing the response. These studies were consistent with each other and yielded moderate quality evidence (with a relatively small total number of participants involved (172) being the only reason to not regard the level of evidence from them as high) that IVIg was ineffective in preventing ET or top‐up transfusions. </p> <p><b>Conclusion</b> </p> <p>Based on all included studies, we could make no conclusions on the benefit of IVIg in preventing ET or top‐up transfusion. However, the two placebo‐controlled trials provided evidence of moderate quality that IVIg was ineffective in preventing ET or top‐up transfusion, and therefore routine use in alloimmune HDN should not be recommended. However, since there was some evidence that IVIg reduced hemolysis (in laboratory studies), future high‐quality studies are needed to determine whether IVIg has limited role in some infants with alloimmune HDN. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003313-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003313-sec-0086"></div> <h3 class="title" id="CD003313-sec-0087">Implications for practice</h3> <section id="CD003313-sec-0087"> <p>Based on the overall outcomes of the review, there is insufficient evidence to conclude that intravenous immunoglobulin (IVIg) is beneficial in neonates with hemolytic disease of the newborn (HDN). We gave particular weight to the results of the only two studies that provide evidence at sufficient low risk of bias to guide routine clinical practice, and that show no reduction in the use of exchange transfusion (ET), or improvement in any other important outcomes of the review. In addition, IVIg has risks that have been identified in other contexts of treatment. Therefore, we believe routine use of IVIg for HDN should not be recommended. </p> <p>The effect of IVIg plus phototherapy compared to phototherapy alone on eventual neurodevelopmental outcomes remains unknown, although there was no difference in neurodevelopmental outcome between these groups in a (small) long‐term follow‐up study (<a href="./references#CD003313-bbs2-0067" title="vanKlinkJM , vanVeenSJ , Smits‐WintjensVE , LindenburgIT , RijkenM , OepkesD , et al. Immunoglobulins in neonates with Rhesus hemolytic disease of the fetus and newborn: long‐term outcome in a randomized trial. Fetal Diagnosis and Therapy2016;39(3):209‐13. ">van Klink 2016</a>). However, since there is some indirect evidence that IVIg reduces hemolysis and because it appears safe in neonates with alloimmune HDN (acknowledging that the combined sample size of all studies is insufficient to assess uncommon, put potentially serious adverse effects), it may have a limited role in special circumstances, such as where ET is impossible, or is considered particularly high risk. Nevertheless, undertaking preparations for ET, including ensuring earliest possible use of intensive phototherapy, and birth at or transfer to a center that can perform ET, would seem to be strongly indicated in high‐risk infants, and should not be abandoned in the expectation that IVIg will be efficacious. </p> </section> <h3 class="title" id="CD003313-sec-0088">Implications for research</h3> <section id="CD003313-sec-0088"> <p>Future research into the role of IVIg in the early treatment of alloimmune HDN may be warranted, especially for infants for whom ET carries particularly high risks. Such a trial should examine the safety and efficacy of IVIg by recording both short‐term outcomes such as the need for transfusion therapy and the incidence of adverse events and also long‐term neurodevelopmental outcomes. Both ETs and (late) top‐up transfusions should be recorded because reduction of ETs can increase the number of top‐up transfusions (<a href="./references#CD003313-bbs2-0057" title="RathME , Smits‐WintjensVE , LindenburgI , BrandA , OepkesD , WaltherFJ , et al. Top‐up transfusions in neonates with Rh hemolytic disease in relation to exchange transfusions. Vox Sanguinis2010;99(1):65‐70. ">Rath 2010</a>). Consideration should also be given to including additional measures to assess the severity of hemolysis such as carboxyhemoglobin or end tidal carbon monoxide. Based on evidence from the two placebo‐controlled trials at low risk of all forms of bias, the conclusion of the review authors is that IVIg is of very limited usefulness in Rh HDN. However, neither of these placebo‐controlled studies enrolled infants with severe established jaundice due to ABO incompatibility. In contrast to Rh incompatibility, ABO incompatibility mainly results in hyperbilirubinemia without significant anemia. This is primarily due to the relatively few group A and B antigenic sites on neonatal red blood cells (<a href="./references#CD003313-bbs2-0051" title="MurrayNA , RobertsIA . Haemolytic disease of the newborn. Archives of Disease in Childhood. Fetal and Neonatal Edition2007;92(2):F83‐8. ">Murray 2007</a>). Furthermore, infants with ABO‐mediated hemolysis often present for neonatal care when they already have severe jaundice. Due to these differences between Rh and ABO incompatibility it is conceivable that IVIg has a different effect in anti‐A or anti‐B‐mediated jaundice. Due to the relative rarity of severe jaundice caused by ABO incompatibility in many countries and the fact that this condition almost always resolves with phototherapy alone (<a href="./references#CD003313-bbs2-0023" title="BhatYR , KumarCG . Morbidity of ABO haemolytic disease in the newborn. Paediatrics and International Child Health2012;32(2):93‐6. ">Bhat 2012</a>), exploring the use of IVIg to treat established jaundice would require a multicenter randomized controlled trial. Based on the discordance of results in this review between trials that were conducted with and without careful blinding of the intervention using a placebo, we recommend that any future trials should either use a placebo or a robust alternative method for blinding of treatment and outcome assessment. Future trials should be well designed and give priority to establishing guidelines for the "conventional" management of alloimmune HDN, focusing on the criteria for performing both top‐up and ETs and on the role of intensive phototherapy. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003313-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003313-sec-0022"></div> <div class="table" id="CD003313-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intravenous immunoglobulin plus phototherapy compared to phototherapy alone for alloimmune hemolytic disease in neonates</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intravenous immunoglobulin plus phototherapy compared to phototherapy alone for alloimmune hemolytic disease in neonates</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> neonates with alloimmune hemolytic disease </p> <p><b>Settings:</b> ‐ </p> <p><b>Intervention:</b> IVIg + phototherapy </p> <p><b>Comparison:</b> phototherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with phototherapy alone</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with IVIg + phototherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Use of ET</b> (≥ 1); all studies </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>658<br/> (9 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.35</b><br/> (0.25 to 0.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>329 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214 fewer per 1000<br/> (247 fewer to 168 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Use of ET</b> (≥ 1); placebo‐controlled studies </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>172<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.98</b><br/> (0.48 to 1.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 fewer per 1000<br/> (80 fewer to 150 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ETs performed per infant</b>; all studies </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>658<br/> (9 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean ETs per infant for all studies was 0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.34 lower<br/> (0.5 lower to 0.17 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ETs performed per infant</b>; placebo‐controlled studies </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>172<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean ETs per infant for placebo‐controlled studies was 0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.04 lower<br/> (0.18 lower to 0.1 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Use of top‐up transfusion in 1st week of life</b>; all studies </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>378<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.05</b><br/> (0.65 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 more per 1000<br/> (45 fewer to 89 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Use of top‐up transfusion after 1st week of life</b>; all studies </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>507<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.16</b><br/> (0.97 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 more per 1000<br/> (7 fewer to 83 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Maximum total serum bilirubin</b> (µmol/L); all studies </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>451<br/> (6 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>10,11,12</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean maximum serum bilirubin (µmol/L) for all studies was 0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 25.39 lower<br/> (34.07 lower to 16.7 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>ET:</b> exchange transfusion; <b>IVIg:</b> intravenous immunoglobulin; <b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> quality<b>:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate</b> quality<b>:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low</b> quality<b>:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low</b> quality<b>:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>In three studies, the method of randomization was not stated and there was inadequate concealment of random sequence (selection bias). In seven studies, there was no blinding of personnel (performance bias) and in five studies, no blinding of outcome assessment (detection bias). Among other potential sources of bias were that mean bilirubin levels at study entry were already higher than the threshold for the outcome (ET) in one study, differences between study groups despite randomization (one study), postrandomization withdrawals or cross‐over between study groups (two studies) and criteria for ET differing between treatment arms (one study). </p> <p><sup>2</sup>Substantial heterogeneity: Chi<sup>2</sup> = 34.63, df = 8 (P = 0.0003), I<sup>2</sup> = 77%. </p> <p><sup>3</sup>Four studies did not clearly specify use of intensive phototherapy (which should be a routine intervention for infants at high risk of ET). </p> <p><sup>4</sup>Total number of participants in these two trials was low, increasing the risk of possible bias. </p> <p><sup>5</sup>Only a few infants needed a second ET. </p> <p><sup>6</sup>In one trial, the methods of randomization and allocation concealment were not stated. In two studies, there was no blinding of personnel (performance bias). </p> <p><sup>7</sup>Combined studies were underpowered for use of top‐up transfusion in 1st week. A total of 378 infants were enrolled in all four trials, and the overall frequency of top‐up transfusion was low (13.8%). </p> <p><sup>8</sup>Substantial heterogeneity: Chi<sup>2</sup> = 15.60, df = 5 (P = 0.008); I<sup>2</sup> = 68%. </p> <p><sup>9</sup>Due to small differences between treatment groups, the combined studies were underpowered for use of top‐up transfusion after 1st week. </p> <p><sup>10</sup>Four studies used no method of blinding the intervention. </p> <p><sup>11</sup>Substantial heterogeneity: Chi<sup>2</sup> = 14.82, df = 5 (P = 0.01); I<sup>2</sup> = 66%. </p> <p><sup>12</sup>Peak serum bilirubin in the control group varied 1.86‐fold between studies; there was considerably greater variation between studies than between groups within studies. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003313-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003313-sec-0023"></div> <section id="CD003313-sec-0024"> <h3 class="title" id="CD003313-sec-0024">Description of the condition</h3> <p>The use of anti‐D immunoglobulin prophylaxis in D‐negative women has led to a marked decline in Rh hemolytic disease of the newborn (HDN) (<a href="./references#CD003313-bbs2-0065" title="UrbaniakSJ , GreissMA . RhD haemolytic disease of the fetus and the newborn. Blood Reviews2000;14:44‐61. ">Urbaniak 2000</a>). Sensitization can occur despite immunoprophylaxis, particularly if it is given too late or in insufficient dose. A proportion of HDN is caused by antibodies to antigens other than D and is, therefore, not preventable with anti‐D immunoglobulin. Fetal therapy has significantly improved outcome in Rh sensitized fetuses, but it does not comprehensively prevent need for neonatal treatment (<a href="./references#CD003313-bbs2-0066" title="vanKampIL , KlumperFJ , MeermanRH , OepkesD , ScherjonSA , KanhaiHH . Treatment of fetal anemia due to red‐cell alloimmunization with intrauterine transfusions in the Netherlands, 1988‐1999. Acta Obstetricia Gynecologica Scandinavica2004;83(8):731‐7. ">van Kamp 2004</a>). Primary modes of postnatal therapy include phototherapy and exchange transfusion (ET) to reduce risk of mortality and kernicterus. Top‐up transfusions are used to treat early and late anemia. In contemporary perinatal centers, 15% to 40% of neonates admitted for Rh or ABO HDN require at least one ET (<a href="./references#CD003313-bbs2-0063" title="SteinerLA , BizzarroMJ , EhrenkranzRA , GallagherPG . A decline in the frequency of neonatal exchange transfusions and its effect on exchange‐related morbidity and mortality. Pediatrics2007;120(1):27‐32. ">Steiner 2007</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>). </p> <p>The safety of ET has been reported for over 50 years. Published mortality rates vary from 0.53% to 4.7% per infant (<a href="./references#CD003313-bbs2-0024" title="BoggsTRJr , WestphalMCJr . Mortality of exchange transfusion. Pediatrics1960;26:745‐55. ">Boggs 1960</a>; <a href="./references#CD003313-bbs2-0053" title="PanagopoulosG , ValaesT , DoxiadisSA . Morbidity and mortality related to exchange transfusion. Journal of Pediatrics1969;74(2):247‐54. ">Panagopoulos 1969</a>; <a href="./references#CD003313-bbs2-0043" title="KeenanWJ , NovakKK , SutherlandJM , BrylaDA , FetterlyKL . Morbidity and mortality associated with exchange transfusion. Pediatrics1985;75 (Suppl)(2 Pt 2):417‐21. ">Keenan 1985</a>; <a href="./references#CD003313-bbs2-0035" title="GuaranRL , DrewJH , WatkinsAM . Jaundice: clinical practice in 88,000 liveborn infants. Australian and New Zealand Journal of Obstetrics1992;32(3):186‐92. ">Guaran 1992</a>; <a href="./references#CD003313-bbs2-0042" title="JacksonJC . Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics1997;99(5):E7. ">Jackson 1997</a>; <a href="./references#CD003313-bbs2-0054" title="PatraK , Storfer‐IsserA , SinerB , MooreJ , HackM . Adverse events associated with neonatal exchange transfusion in the 1990s. Journal of Pediatrics2004;144(5):626‐31. ">Patra 2004</a>; <a href="./references#CD003313-bbs2-0022" title="BadieeZ . Exchange transfusion in neonatal hyperbilirubinaemia: experience in Isfahan, Iran. Singapore Medical Journal2007;48(5):421‐3. ">Badiee 2007</a>). ET‐related death is more common in sick or premature infants than in healthy term infants (<a href="./references#CD003313-bbs2-0024" title="BoggsTRJr , WestphalMCJr . Mortality of exchange transfusion. Pediatrics1960;26:745‐55. ">Boggs 1960</a>; <a href="./references#CD003313-bbs2-0043" title="KeenanWJ , NovakKK , SutherlandJM , BrylaDA , FetterlyKL . Morbidity and mortality associated with exchange transfusion. Pediatrics1985;75 (Suppl)(2 Pt 2):417‐21. ">Keenan 1985</a>; <a href="./references#CD003313-bbs2-0042" title="JacksonJC . Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics1997;99(5):E7. ">Jackson 1997</a>; <a href="./references#CD003313-bbs2-0063" title="SteinerLA , BizzarroMJ , EhrenkranzRA , GallagherPG . A decline in the frequency of neonatal exchange transfusions and its effect on exchange‐related morbidity and mortality. Pediatrics2007;120(1):27‐32. ">Steiner 2007</a>). Risks related to ET include adverse cardiorespiratory events; catheter‐related complications; those related to the use of blood products; metabolic derangements; and other serious complications such as pulmonary hemorrhage, necrotizing enterocolitis and bowel perforation. In the last two decades, ET‐related risks have been reported to be as high as 74%, although the incidence of severe adverse events is approximately 3‐10% (<a href="./references#CD003313-bbs2-0041" title="IpS , ChungM , KuligJ , O'BrienR , SegeR , GlickenS , et al. An evidence‐based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics2004;114(1):e130‐53. ">Ip 2004</a>; <a href="./references#CD003313-bbs2-0054" title="PatraK , Storfer‐IsserA , SinerB , MooreJ , HackM . Adverse events associated with neonatal exchange transfusion in the 1990s. Journal of Pediatrics2004;144(5):626‐31. ">Patra 2004</a>; <a href="./references#CD003313-bbs2-0022" title="BadieeZ . Exchange transfusion in neonatal hyperbilirubinaemia: experience in Isfahan, Iran. Singapore Medical Journal2007;48(5):421‐3. ">Badiee 2007</a>; <a href="./references#CD003313-bbs2-0063" title="SteinerLA , BizzarroMJ , EhrenkranzRA , GallagherPG . A decline in the frequency of neonatal exchange transfusions and its effect on exchange‐related morbidity and mortality. Pediatrics2007;120(1):27‐32. ">Steiner 2007</a>). Because improved perinatal care has reduced the need for ET, the complication rate could increase as clinicians become less experienced with the procedure (<a href="./references#CD003313-bbs2-0063" title="SteinerLA , BizzarroMJ , EhrenkranzRA , GallagherPG . A decline in the frequency of neonatal exchange transfusions and its effect on exchange‐related morbidity and mortality. Pediatrics2007;120(1):27‐32. ">Steiner 2007</a>). However, <a href="./references#CD003313-bbs2-0063" title="SteinerLA , BizzarroMJ , EhrenkranzRA , GallagherPG . A decline in the frequency of neonatal exchange transfusions and its effect on exchange‐related morbidity and mortality. Pediatrics2007;120(1):27‐32. ">Steiner 2007</a> reported that over a 21‐year period, despite a sharp decline in the number of ETs performed, there was no increase in morbidity and mortality.  </p> </section> <section id="CD003313-sec-0025"> <h3 class="title" id="CD003313-sec-0025">Description of the intervention</h3> <p>Intravenous immunoglobulin (IVIg) is an alternative therapy that may be effective in treating alloimmune HDN. In 1987, the first report of successful treatment of late anemia due to E‐incompatibility with IVIg was published (<a href="./references#CD003313-bbs2-0038" title="HaraT , MizunoY , KawanoM , UekiY , UedaK . Treatment of immune hemolytic anaemia with gammaglobulin. Journal of Pediatrics1987;110(5):817‐8. ">Hara 1987</a>). Subsequent case reports and case series reported success of IVIg treatment in neonates with both Rh or ABO incompatibility (<a href="./references#CD003313-bbs2-0044" title="KuboS , ArigaT , TsunetaH , IshiiT . Can high‐dose immunoglobulin therapy be indicated in neonatal rhesus haemolysis? A successful case of haemolytic disease due to rhesus (c+E) incompatibility. European Journal of Pediatrics1991;150(7):507‐8. ">Kubo 1991</a>; <a href="./references#CD003313-bbs2-0060" title="SatoK , HaraT , KondoT , IwoaH , HondaS , UedaK . High‐dose intravenous gammaglobulin therapy for neonatal immune haemolytic jaundice due to blood group incompatibility. Acta Paediatrica Scandinavica1991;80(2):163‐6. ">Sato 1991</a>; <a href="./references#CD003313-bbs2-0028" title="ErgazZ , AradI . Intravenous immunoglobulin therapy in neonatal immune hemolytic jaundice. Journal of Perinatal Medicine1993;21(3):183‐7. ">Ergaz 1993</a>). However, <a href="./references#CD003313-bbs2-0036" title="HammermanC , KaplanM , VremanHJ , StevensonDK . Intravenous immune globulin in neonatal ABO isoimmunization: factors associated with clinical efficacy. Biology of the Neonate1996;70(2):69‐74. ">Hammerman 1996a</a> found a reduced or no response to IVIg treatment in infants with ABO incompatibility who had early and severe hemolysis. Since the early 1990s, several quasi‐randomized or randomized controlled trials on the use of IVIg (including variations on timing of administration and dose) to reduce ET have been published (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>; <a href="./references#CD003313-bbs2-0010" title="AticiA , SatarM , GöğebakanM . Intravenous immunoglobulin therapy for neonatal hyperbilirubinemia due to ABO or Rh incompatibility [ABO veya Rh Uyuşmazliğinin neden olduğu neonatal hiperbilirübinemide intravenöz immüglobülin tedavisi]. Çocuk Sağliği ve Hastaliklari Dergisi1996;39:623‐30. ">Atici 1996</a>; <a href="./references#CD003313-bbs2-0011" title="GarciaMG , CorderoG , MucinoP , SalinasV , FernandezLA , ChristensenRD . Intravenous immunoglobulin (IVIg) administration as a treatment for Rh hemolytic jaundice in Mexico City. Pediatric Research2004;55:65. ">Garcia 2004</a>; <a href="./references#CD003313-bbs2-0012" title="GirishG , ChawlaD , AgarwalR , PaulVK , DeorariAK . Efficacy of two dose regimen of intravenous immunoglobulin in Rh hemolytic disease of newborn ‐ a randomized controlled trial. Indian Pediatrics2008;45(8):653‐9. ">Girish 2008</a>; <a href="./references#CD003313-bbs2-0013" title="HematyarM , ZareianM . The effects of intravenous immunoglobulin(IVIG) in hemolytic jaundice of the newborn due to ABO and Rh isoimmunization. Acta Paediatrica2011;100(Suppl 463):13‐83. ">Hematyar 2011</a>; <a href="./references#CD003313-bbs2-0014" title="HuangWM , ChenHW , LiN , YangM , JiaoPY . Clinical study of early interventions for ABO hemolytic disease of the newborn. Nan Fang Yi Ke da Xue Xue Bao [Journal of Southern Medical University]2006;26(9):1350‐1. ">Huang 2006</a>; <a href="./references#CD003313-bbs2-0015" title="LiuYF , ZouCC , YangHQ , LouLJ . Comparison of therapeutic efficacy for neonatal ABO hemolytic disease treated with intravenous immunoglobulin G by different modes of administration. Zhongguo Shi Yan Xue Ye Xue za Zhi [Journal of Experimental Hematology]2016;24(6):1842‐5. ">Liu 2016</a>; <a href="./references#CD003313-bbs2-0016" title="PishvaN , MadaniA , HomayoonK . Prophylactic intravenous immunoglobulin in neonatal immune hemolytic jaundice. Iranian Journal of Medical Sciences2000;25(3 &amp; 4):129‐33. ">Pishva 2000</a>; <a href="./references#CD003313-bbs2-0017" title="RüboJ , WahnV . Influence of high dosage immuno‐globulin therapy on hyperbilirubinemia in rhesus‐hemolytic disease. A cooperative study [Kooperative Studie zum Einfluß einer hochdosierten Immunglobulintherapie auf die Hyperbilirubinämie bei Rhesusinkompatibilität]. Monatsschrift fur Kinderheilkunde1996;144:516‐9. ">Rübo 1996</a>; <a href="./references#CD003313-bbs2-0018" title="SpinelliSL , OtheguyLE , LarguiaMA . Postnatal use of high‐dose intravenous immunoglobulin therapy in rhesus hemolytic disease treatment. Journal of Perinatal Medicine2001;29(Suppl 1):683. ">Spinelli 2001</a>; <a href="./references#CD003313-bbs2-0019" title="VotoLS , SexerH , FerreiroG , TavosnanskaJ , OrtiJ , MathetER , et al. Neonatal administration of high‐dose intravenous immunoglobulin in rhesus hemolytic disease. Journal of Perinatal Medicine1995;23(6):443‐51. ">Voto 1995</a>; <a href="./references#CD003313-bbs2-0020" title="WangMQ , GuoYX , YuSQ . Curative observation of ABO HDN treated by immunogbulin. Shanxi.Medical Journal2002;31:239‐40. ">Wang 2002</a>). </p> <p>The potential benefits of IVIg over ET include that the treatment is less complicated and less labor intensive. In addition, IVIg could allow safe treatment of some infants in less sophisticated neonatal units, or avoid delaying treatment while transferring infants for ET. Comprehensive assessment of IVIg in premature infants, particularly in the treatment of sepsis, has shown that it is safe and well tolerated (<a href="./references#CD003313-bbs2-0040" title="INIS Collaborative Group, BrocklehurstP , FarrellB , KingA , JuszczakE , DarlowB , et al. Treatment of neonatal sepsis with intravenous immune globulin. New England Journal of Medicine2011;365(13):1201‐11. ">INIS Collaborative Group 2011</a>). It is a well‐established therapy for alloimmune thrombocytopenia due to maternal and fetal human platelet antigen incompatibility (<a href="./references#CD003313-bbs2-0068" title="WinkelhorstD , OepkesD , LoprioreE . Fetal and neonatal alloimmune thrombocytopenia: evidence based antenatal and postnatal management strategies. Expert Review of Hematology2017;10(8):729‐37. ">Winkelhorst 2017</a>). The risk of transmission of viral infection is extremely low (<a href="./references#CD003313-bbs2-0031" title="FischerGW . Therapeutic uses of intravenous gammaglobulin for pediatric infections. Pediatric Clinics of North America1988;35(3):517‐33. ">Fischer 1988</a>). Hemolysis and acute renal failure are uncommon complications of IVIg treatment (<a href="./references#CD003313-bbs2-0026" title="CopelanEA , StrohmPL , KennedyMS , TutschkaPJ . Hemolysis following intravenous immune globulin therapy. Transfusion1986;26(5):410‐12. ">Copelan 1986</a>). One study showed an increased incidence of sepsis in premature infants receiving prophylactic IVIg (<a href="./references#CD003313-bbs2-0049" title="MagnyJF , Bremard‐OuryC , BraultD , MenguyC , VoyerM , LandaisP , et al. Intravenous immunoglobulin therapy for prevention of infection in high‐risk premature infants: report of a multicenter, double blind study. Pediatrics1991;88:437‐43. ">Magny 1991</a>). Since about 2010, several cases of necrotizing enterocolitis in infants with HDN treated with IVIg have been reported (<a href="./references#CD003313-bbs2-0030" title="Figueras‐AloyJ , Rodríguez‐MiguélezJM , Iriondo‐SanzM , Salvia‐RoigesMD , Botet‐MussonsF , Carbonell‐EstranyX . Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease. Pediatrics2010;125(1):139‐44. ">Figueras‐Aloy 2010</a>; <a href="./references#CD003313-bbs2-0027" title="CorvagliaL , LegnaniE , GallettiS , ArcuriS , AcetiA , FaldellaG . Intravenous immunoglobulin to treat neonatal alloimmune haemolytic disease. Journal of Maternal‐fetal &amp; Neonatal Medicine2012;25(12):2782‐5. ">Corvaglia 2012</a>; <a href="./references#CD003313-bbs2-0069" title="YangY , PanJJ , ZhouXG , ZhouXY , ChengR , HuYH . The effect of immunoglobulin treatment for hemolysis on the incidence of necrotizing enterocolitis ‐ a meta‐analysis. European Review for Medical and Pharmacological Sciences2016;20(18):3902‐10. ">Yang 2016</a>+ </p> <p>). Other rare serious adverse effects of IVIg have been described in pediatric and adult cohorts, but not in newborns (<a href="./references#CD003313-bbs2-0045" title="KumarA , TeuberSS , GershwinME . Intravenous immunoglobulin: striving for appropriate use. International Archives of Allergy and Immunology2006;140(3):185‐98. ">Kumar 2006</a>). </p> </section> <section id="CD003313-sec-0026"> <h3 class="title" id="CD003313-sec-0026">How the intervention might work</h3> <p>IVIg might reduce the rate of hemolysis in alloimmune HDN by nonspecific blockade of Fc‐receptors on the macrophages that are thought to mediate the destruction of antibody‐coated red cells (<a href="./references#CD003313-bbs2-0064" title="UrbaniakSJ . ADCC (K‐cell) lysis of human erythrocytes sensitized with rhesus alloantibodies. II. Investigation into the mechanism of lysis. British Journal of Haematology1979;42(2):315‐25. ">Urbaniak 1979</a>). <a href="./references#CD003313-bbs2-0029" title="ErgazZ , GrossD , Bar‐OzB , PelegO , AradI . Carboxyhemoglobin levels in neonatal immune hemolytic jaundice treated with intravenous gammaglobulin. Vox Sanguinis1995;69(2):95‐9. ">Ergaz 1995</a> demonstrated a decline in carboxyhemoglobin levels in four of five infants treated with IVIg for alloimmune HDN. <a href="./references#CD003313-bbs2-0037" title="HammermanC , VremanHJ , KaplanM , StevensonDK . Intravenous immune globulin in neonatal immune hemolytic disease: does it reduce hemolysis?. Acta Paediatrica1996;85(11):1351‐3. ">Hammerman 1996b</a> demonstrated a significant reduction in carboxyhemoglobin levels in 19 of 26 Coombs‐positive infants treated with IVIg. Carboxyhemoglobin levels are a sensitive index of hemolysis and hence these studies suggest that immunoglobulin could decrease hemolysis. IVIg is typically formulated in 6% to 12% solutions, so at doses of 0.5 g/kg to 1 g/kg the volume administered is 4 mL/kg to 16 mL/kg. It is possible that this is a sufficient fluid bolus to reduce bilirubin levels modestly through dilution, temporarily slowing their rate of rise and allowing more time for intensive phototherapy to have effect. </p> </section> <section id="CD003313-sec-0027"> <h3 class="title" id="CD003313-sec-0027">Why it is important to do this review</h3> <p>This is an update of a Cochrane Review first published in 2002. Although results of the previous review showed a significant reduction in the need for ET in infants treated with IVIg, the applicability of the results was limited because none of three included studies was at low risk of bias. Nevertheless, American Academy of Pediatrics (AAP) guidelines recommend the administration of 0.5 g/kg to 1 g/kg IVIg in alloimmune HDN if total serum bilirubin (TSB) is rising despite intensive phototherapy or if TSB level is within 34 µmol/L to 51 µmol/L (2 mg/dL to 3 mg/dL) of exchange level (<a href="./references#CD003313-bbs2-0021" title="American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics2004;114(1):297‐316. ">AAP 2004</a>). As a result of these guidelines, despite the equivocal conclusions of the previous Cochrane Review, the use of IVIg in alloimmune HDN has become widespread in many countries. However, supplies of IVIg are limited and it does present some hazards. Therefore, use of IVIg should be restricted to treatment of conditions for which it is of confirmed benefit. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003313-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003313-sec-0028"></div> <p>To assess the effect and complications of IVIg in newborn infants with alloimmune HDN on the need for and number of exchange transfusions. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003313-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003313-sec-0029"></div> <section id="CD003313-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003313-sec-0031"> <h4 class="title">Types of studies</h4> <p>All randomized and quasi‐randomized controlled trials of IVIg in the treatment of alloimmune HDN. </p> </section> <section id="CD003313-sec-0032"> <h4 class="title">Types of participants</h4> <p>Neonates with alloimmune HDN due to either Rh (or other red cell antigens) or ABO blood group antibodies with or without any other blood group antibodies. </p> </section> <section id="CD003313-sec-0033"> <h4 class="title">Types of interventions</h4> <p>IVIg given for treatment of alloimmune HDN versus control (placebo or 'standard care'). Phototherapy, which is widely regarded as a safe and effective standard treatment may have been used in both IVIG and control groups. Early and late IVIg administration were defined (for this review) as IVIg started within (early) or after (late) the first 12 hours of life. Studies must have included predefined criteria for both IVIg and ET therapy. </p> </section> <section id="CD003313-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD003313-sec-0035"> <h5 class="title">Primary outcomes</h5> <p>Efficacy:</p> <p> <ul id="CD003313-list-0001"> <li> <p>use of ET (proportion of infants receiving one or more ETs);</p> </li> <li> <p>ETs performed per infant.</p> </li> </ul> </p> </section> <section id="CD003313-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p>Efficacy:</p> <p> <ul id="CD003313-list-0002"> <li> <p>use of top‐up transfusion(s) in first week of life (% of infants);</p> </li> <li> <p>number of top‐up transfusions performed in first week of life per infant;</p> </li> <li> <p>use of top‐up transfusion(s) after first week of life (% of infants);</p> </li> <li> <p>number of top‐up transfusions performed after first week of life per infant;</p> </li> <li> <p>maximum TSB (µmol/L (mg/dL));</p> </li> <li> <p>duration of phototherapy (days);</p> </li> <li> <p>duration of hospitalization (days);</p> </li> <li> <p>incidence of sensorineural hearing loss (any severity);</p> </li> <li> <p>incidence of kernicterus;</p> </li> <li> <p>incidence of cerebral palsy.</p> </li> </ul> </p> <p>Safety:</p> <p> <ul id="CD003313-list-0003"> <li> <p>neonatal mortality;</p> </li> <li> <p>incidence of adverse reactions possibly related to the use of IVIg or ET (statement of adverse events from individual trials only). </p> </li> </ul> </p> </section> </section> </section> <section id="CD003313-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003313-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We performed electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library<i>)</i>, PubMed, Embase (Ovid), Web of Science, CINAHL (EBSCOhost), Emcare and Academic Search Premier. The subject query was applied in all databases taking into account the terminological differences between these databases. The query consisted of the combination of four subjects: immunoglobulins, alloimmune hemolytic jaundice, newborn infants and randomized controlled trials. Various synonyms and related terms for all subjects were used. Two search strategies were used: the first strategy was limited to randomized trials and systematic reviews, the second strategy included only the subjects immunoglobulins and alloimmune hemolytic disease (and synonyms and related terms for those subjects). The search was performed on 19 May 2017. The bibliographic databases yielded 1565 references in total of which titles and abstracts were screened. The complete search strategy is attached in the appendix "Complete Search Strategy." In addition to database searches, we searched the trial registers ClinicalTrials.gov and controlled‐trials.com. We applied no language restrictions. </p> </section> <section id="CD003313-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of all included and excluded trials and relevant reviews for further relevant studies. </p> </section> </section> <section id="CD003313-sec-0040"> <h3 class="title" id="CD003313-sec-0040">Data collection and analysis</h3> <p>We used the standard method of Cochrane and its Neonatal Review Group.</p> <section id="CD003313-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently screened the titles and abstracts of all references for possible inclusion using predefined criteria for inclusion (see below). We obtained a full‐text version of the article if a report appeared to meet inclusion criteria for the review, or if it was not clear based on title and abstract. We resolved any disagreements through discussion with other review authors. </p> <p>The inclusion criteria for this review were:</p> <p> <ul id="CD003313-list-0004"> <li> <p>randomized and quasi‐randomized controlled trials;</p> </li> <li> <p>study compared IVIg with any definition of "standard care" plus placebo, or with any definition of "standard care" without placebo; </p> </li> <li> <p>study included neonates with alloimmune HDN due to either ABO or Rh blood group antibodies with or without any other blood group antibodies; </p> </li> <li> <p>study measured ETs (primary outcome) for each study arm or at least one of the secondary outcomes (see below) (or both) for each study arm; </p> </li> <li> <p>study used predefined criteria for both IVIg and ET therapy.</p> </li> </ul> </p> </section> <section id="CD003313-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data using a data collection form that was pilot tested before use. We resolved any disagreements through discussion and if necessary with the help of a third review author blinded to trial author, institution and journal of publication. One review author contacted authors of studies that did not report all required data or information. One review author entered data into Review Manager 5 (<a href="./references#CD003313-bbs2-0058" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>; <a href="./references#CD003313-bbs2-0059" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), and at least one review author checked them. </p> </section> <section id="CD003313-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias of included studies using the 'Risk of bias' tool as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003313-bbs2-0039" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). The following items for risk of bias were assessed: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other sources of bias. Each item was rated as 'low risk of bias', 'unclear risk of bias' or 'high risk of bias.' Any differences of opinion were discussed with a third blinded review author until consensus was reached. For selective reporting, we used the following criteria to rate a study as 'low risk of bias:' </p> <p> <ul id="CD003313-list-0005"> <li> <p>for studies enrolling neonates with Rh or both Rh and ABO HDN: reporting (in paper or subsequent correspondence) at least one outcome related to each of ET, bilirubin and top‐up transfusion, plus adverse effects and hospitalization. </p> </li> <li> <p>for studies enrolling only neonates with ABO HDN: reporting (in paper or subsequent correspondence) at least one outcome related to each of ET and bilirubin, plus adverse effects and hospitalization. Top‐up transfusion was not considered to be a preferred outcome measure because anemia requiring treatment is an unusual consequence of ABO alloimmune hemolysis; </p> </li> <li> <p>study protocols or methods section of papers should not describe an intention to report outcomes that were not subsequently reported in the paper. </p> </li> </ul> </p> </section> <section id="CD003313-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated the risk ratio (RR) and risk difference (RD) for categorical outcomes, such as the incidence of ET. We calculated the mean difference (MD) for continuous variables, such as the maximum bilirubin level. We also calculated the number needed to treat for an additional beneficial outcome (NNTB) to avoid ET, where the assumed control risk was derived from the mean baseline risk from the studies (<a href="./references#CD003313-bbs2-0061" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors. GRADE Working Group. GRADE handbook for grading quality of evidence and strength of recommendations. Available from www.guidelinedevelopment.org/handbookUpdated October 2013. ">Schünemann 2013</a>). We presented 95% confidence intervals (CI). </p> </section> <section id="CD003313-sec-0045"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators for missing information about study design, results or both. </p> </section> <section id="CD003313-sec-0046"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by determining whether clinical characteristics of participants, interventions, outcome measures and timing of outcome measurements were similar for included studies. We assessed statistical heterogeneity using Chi<sup>2</sup> and I<sup>2</sup> tests. An I<sup>2</sup> statistic of 50% or greater was considered as substantial or considerable heterogeneity according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003313-bbs2-0039" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD003313-sec-0047"> <h4 class="title">Assessment of reporting biases</h4> <p>We contacted investigators to request missing outcome data when selective reporting bias was suspected based on the criteria described under <a href="#CD003313-sec-0043">Assessment of risk of bias in included studies</a>. </p> <p>If the data remained unavailable and the absence was thought to introduce serious bias, the study was excluded. </p> </section> <section id="CD003313-sec-0048"> <h4 class="title">Data synthesis</h4> <p>We used Review Manager 5 to synthesize the available data (<a href="./references#CD003313-bbs2-0059" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). Whether we used a fixed‐effect model or a random‐effects model depended on the level of clinical heterogeneity and the results of the Chi<sup>2</sup> test and I<sup>2</sup> statistic for heterogeneity (<a href="./references#CD003313-bbs2-0039" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). If there was substantial heterogeneity, we used a random‐effects model was used and examined the sources of heterogeneity. If there was no substantial statistical heterogeneity, we used a fixed‐effect model. </p> <section id="CD003313-sec-0049"> <h5 class="title">Quality of evidence</h5> <p>We used the GRADE approach, as outlined in the GRADE Handbook (<a href="./references#CD003313-bbs2-0061" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors. GRADE Working Group. GRADE handbook for grading quality of evidence and strength of recommendations. Available from www.guidelinedevelopment.org/handbookUpdated October 2013. ">Schünemann 2013</a>), to assess the quality of evidence for the following (clinically relevant) outcomes: </p> <p> <ul id="CD003313-list-0006"> <li> <p>use of ET (proportion of infants receiving one or more ETs; assessment for all studies and separately for placebo‐controlled studies; </p> </li> <li> <p>ETs per infant; assessment for all studies and separately for placebo‐controlled studies;</p> </li> <li> <p>use of top‐up transfusion(s) in first week of life (% of infants); all studies;</p> </li> <li> <p>use of top‐up transfusion(s) after first week of life (% of infants); all studies;</p> </li> <li> <p>maximum serum bilirubin; all studies.</p> </li> </ul> </p> <p>Two review authors independently assessed the quality of the evidence for each of the outcomes. We considered evidence from randomized controlled trials as high quality but downgraded the evidence one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates and presence of publication bias. We used the GRADEpro Guideline Development Tool to create a 'Summary of findings' table to report the quality of the evidence (<a href="./references#CD003313-bbs2-0034" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 16 October 2017. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT</a>). </p> <p>The GRADE approach results in an assessment of the quality of a body of evidence in one of four grades. </p> <p> <ul id="CD003313-list-0007"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> </section> <section id="CD003313-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analyses were conducted to determine if effects depend on:</p> <p> <ul id="CD003313-list-0008"> <li> <p>population:</p> </li> </ul> <ul class="plain" id="CD003313-list-0009"> <li> <ul id="CD003313-list-0010"> <li> <p>Rh incompatibility;</p> </li> <li> <p>gestational age at birth (less than 37 weeks and 37 weeks or greater);</p> </li> </ul> </li> </ul> <ul id="CD003313-list-0011"> <li> <p>intervention:</p> </li> </ul> <ul class="plain" id="CD003313-list-0012"> <li> <ul id="CD003313-list-0013"> <li> <p>early administration of IVIg: start of IVIg 12 hours or less after birth;</p> </li> <li> <p>late administration of IVIg: start of IVIg more than 12 hours after birth;</p> </li> <li> <p>single versus multiple doses.</p> </li> </ul> </li> </ul> </p> <p>As in contemporary care intensive phototherapy is standard care for ABO incompatibility and therefore ETs hardly ever occur in this subgroup nowadays, no subgroup analysis was performed for ABO incompatibility only. </p> </section> <section id="CD003313-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted a sensitivity analysis based on whether or not the included studies used a placebo and treatment blinding (which had potential to reduce performance bias and detection bias). The two studies that used a placebo were also at low risk of other forms of bias in that they used random sequence generation, allocation concealment, reported complete outcome data for all prespecified outcomes and did not have other apparent risks of bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003313-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003313-sec-0052"></div> <section id="CD003313-sec-0053"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD003313-sec-0099" title="">Characteristics of included studies</a>; <a href="./references#CD003313-sec-0100" title="">Characteristics of excluded studies</a>; and Characteristics of studies awaiting classification tables. </p> <section id="CD003313-sec-0054"> <h4 class="title">Results of the search</h4> <p>The search conducted up to 19 May 2017 identified 1565 references (see: <a href="./appendices#CD003313-sec-0092">Appendix 1</a>). After title and abstract screening, the full text of 27 references was screened. After full text screening, nine studies were included in the meta‐analysis (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). Details of the studies are given in the <a href="./references#CD003313-sec-0099" title="">Characteristics of included studies</a> table. Eleven studies were permanently excluded from this review. Details of these studies are given in the <a href="./references#CD003313-sec-0100" title="">Characteristics of excluded studies</a> table. We found no additional studies searching reference lists of included and excluded studies and relevant reviews. A flow diagram of the study selection process is presented in <a href="#CD003313-fig-0001">Figure 1</a>. No additional studies were included after an additional search for ongoing studies in the trial registers ClinicalTrials.gov and controlled‐trials.com. </p> <div class="figure" id="CD003313-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram of study selection process. IVIg: intravenous immunoglobulin; RCT: randomized controlled trial." data-id="CD003313-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram of study selection process. IVIg: intravenous immunoglobulin; RCT: randomized controlled trial. </p> </div> </div> </div> </section> <section id="CD003313-sec-0055"> <h4 class="title">Included studies</h4> <p>The review included nine randomized controlled trials published between 1992 and 2013.</p> <section id="CD003313-sec-0056"> <h5 class="title">Participants</h5> <p>The nine studies included 658 participants. Five studies included only infants with Rh incompatibility (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). One study included only infants with ABO incompatibility (<a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>). Two studies enrolled mostly infants with ABO incompatibility but also some with Rh incompatibility and both ABO and Rh incompatibility (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>: 93 ABO, 16 Rh, seven both; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>: 21 ABO, 13 Rh). <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a> included 34 infants with ABO incompatibility, 18 with Rh incompatibility, two with "subgroup" incompatibility and seven with "more than one incompatibilities." Only <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a> reported results for each type of incompatibility separately and <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a> provided this information through correspondence. Four studies enrolled only term infants of 37 weeks of gestation or greater (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>). None of the studies only included premature infants of less than 37 weeks of gestation. <a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a> did not describe details of the gestational age at birth of enrolled infants. <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a> and <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a> provided outcomes for term and preterm infants separately. </p> </section> <section id="CD003313-sec-0057"> <h5 class="title">Interventions</h5> <p>Seven of nine studies that met the inclusion criteria examined the effect of a single dose of IVIg in combination with phototherapy (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). One study examined multiple doses (<a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>), and one study compared groups treated with a single dose or multiple doses with a control group (<a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>), but was inconsistent in describing which group received a single dose or multiple doses of IVIg and therefore this study was excluded from the (planned) subgroup analysis of single and multiple doses. Two studies used a placebo in addition to phototherapy for the control groups (<a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). The intensity and topography of phototherapy fits the definition of intensive phototherapy in only three studies (<a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a> used an obsolete model with three overhead lights from a single angle and <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a> did not use a phototherapy blanket beneath the baby. The remainder of included studies did not describe the intensity and topography of phototherapy in sufficient detail to allow a conclusion as to whether it is reasonable to describe it as intensive phototherapy. Five studies started IVIg 12 hours or less after birth (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>), and three studies started IVIg more than 12 hours after birth (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>). <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a> started IVIg within 12 hours in nine neonates and more than 12 hours in 47 neonates, but they did not report outcomes for early and late IVIg administration separately. </p> <p>Since phototherapy was used in both treatment and control groups in all studies and is now considered standard of care in HDN, this review is effectively an analysis of the effectiveness of IVIg plus phototherapy versus phototherapy alone. </p> </section> <section id="CD003313-sec-0058"> <h5 class="title">Outcomes</h5> <p>All included studies reported ET as the primary outcome. Six studies reported mean (or median) number of ETs per infant (<a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>) or supplied enough data to calculate these (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>). The authors of four studies provided unpublished data (standard deviation or mean, or both) for ET (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). Four studies reported the maximum bilirubin level (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). Two studies provided unpublished data on maximum bilirubin levels (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>). Although all studies commented on the duration of phototherapy in their results, only seven studies reported or subsequently provided the numerical data (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). These studies all used predefined criteria for commencing phototherapy but not all for ceasing it. Six studies reported or subsequently provided numerical data on the duration of hospitalization (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). Only two studies reported (after correspondence) predefined criteria for hospital discharge (<a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). Six studies included top‐up transfusion as an outcome (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>). Three studies provided additional data on top‐up transfusions (<a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a> did not report top‐up transfusions separately for the first week and after the first week of life, but subsequently provided this information. <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a> had a follow‐up period of only one week after discharge. Three studies reported predefined criteria for top‐up transfusions (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>), and one study later provided data through correspondence (<a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). All studies reported short‐term adverse events. None of the included studies reported data on neurodevelopmental outcomes. Two studies provided additional information on neurodevelopmental outcomes (<a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). </p> </section> </section> <section id="CD003313-sec-0059"> <h4 class="title">Excluded studies</h4> <p>We excluded 11 studies. One study only compared groups with a high or a low dose of IVIg (<a href="./references#CD003313-bbs2-0012" title="GirishG , ChawlaD , AgarwalR , PaulVK , DeorariAK . Efficacy of two dose regimen of intravenous immunoglobulin in Rh hemolytic disease of newborn ‐ a randomized controlled trial. Indian Pediatrics2008;45(8):653‐9. ">Girish 2008</a>), and four studies were only reported in abstract form and our request for additional information was not (sufficiently) answered (<a href="./references#CD003313-bbs2-0016" title="PishvaN , MadaniA , HomayoonK . Prophylactic intravenous immunoglobulin in neonatal immune hemolytic jaundice. Iranian Journal of Medical Sciences2000;25(3 &amp; 4):129‐33. ">Pishva 2000</a>; <a href="./references#CD003313-bbs2-0018" title="SpinelliSL , OtheguyLE , LarguiaMA . Postnatal use of high‐dose intravenous immunoglobulin therapy in rhesus hemolytic disease treatment. Journal of Perinatal Medicine2001;29(Suppl 1):683. ">Spinelli 2001</a>; <a href="./references#CD003313-bbs2-0013" title="HematyarM , ZareianM . The effects of intravenous immunoglobulin(IVIG) in hemolytic jaundice of the newborn due to ABO and Rh isoimmunization. Acta Paediatrica2011;100(Suppl 463):13‐83. ">Hematyar 2011</a>; <a href="./references#CD003313-bbs2-0015" title="LiuYF , ZouCC , YangHQ , LouLJ . Comparison of therapeutic efficacy for neonatal ABO hemolytic disease treated with intravenous immunoglobulin G by different modes of administration. Zhongguo Shi Yan Xue Ye Xue za Zhi [Journal of Experimental Hematology]2016;24(6):1842‐5. ">Liu 2016</a>). Three studies did not report predefined criteria for the primary outcome ET (<a href="./references#CD003313-bbs2-0020" title="WangMQ , GuoYX , YuSQ . Curative observation of ABO HDN treated by immunogbulin. Shanxi.Medical Journal2002;31:239‐40. ">Wang 2002</a>; <a href="./references#CD003313-bbs2-0011" title="GarciaMG , CorderoG , MucinoP , SalinasV , FernandezLA , ChristensenRD . Intravenous immunoglobulin (IVIg) administration as a treatment for Rh hemolytic jaundice in Mexico City. Pediatric Research2004;55:65. ">Garcia 2004</a>; <a href="./references#CD003313-bbs2-0014" title="HuangWM , ChenHW , LiN , YangM , JiaoPY . Clinical study of early interventions for ABO hemolytic disease of the newborn. Nan Fang Yi Ke da Xue Xue Bao [Journal of Southern Medical University]2006;26(9):1350‐1. ">Huang 2006</a>). One study did not report any outcome in a usable form for meta‐analysis (<a href="./references#CD003313-bbs2-0019" title="VotoLS , SexerH , FerreiroG , TavosnanskaJ , OrtiJ , MathetER , et al. Neonatal administration of high‐dose intravenous immunoglobulin in rhesus hemolytic disease. Journal of Perinatal Medicine1995;23(6):443‐51. ">Voto 1995</a>). Two studies were excluded due to methodological or ethical (or both) concerns (<a href="./references#CD003313-bbs2-0010" title="AticiA , SatarM , GöğebakanM . Intravenous immunoglobulin therapy for neonatal hyperbilirubinemia due to ABO or Rh incompatibility [ABO veya Rh Uyuşmazliğinin neden olduğu neonatal hiperbilirübinemide intravenöz immüglobülin tedavisi]. Çocuk Sağliği ve Hastaliklari Dergisi1996;39:623‐30. ">Atici 1996</a>; <a href="./references#CD003313-bbs2-0017" title="RüboJ , WahnV . Influence of high dosage immuno‐globulin therapy on hyperbilirubinemia in rhesus‐hemolytic disease. A cooperative study [Kooperative Studie zum Einfluß einer hochdosierten Immunglobulintherapie auf die Hyperbilirubinämie bei Rhesusinkompatibilität]. Monatsschrift fur Kinderheilkunde1996;144:516‐9. ">Rübo 1996</a>). Details of excluded studies are given in the <a href="./references#CD003313-sec-0100" title="">Characteristics of excluded studies</a> table. </p> <section id="CD003313-sec-0060"> <h5 class="title">Additional data</h5> <p>We attempted to contact the authors of all studies (except for the six studies that were identified for the previous review (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0019" title="VotoLS , SexerH , FerreiroG , TavosnanskaJ , OrtiJ , MathetER , et al. Neonatal administration of high‐dose intravenous immunoglobulin in rhesus hemolytic disease. Journal of Perinatal Medicine1995;23(6):443‐51. ">Voto 1995</a>; <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0018" title="SpinelliSL , OtheguyLE , LarguiaMA . Postnatal use of high‐dose intravenous immunoglobulin therapy in rhesus hemolytic disease treatment. Journal of Perinatal Medicine2001;29(Suppl 1):683. ">Spinelli 2001</a>; <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>) to request further methodological information and results. We successfully contacted the authors of 11 papers (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0017" title="RüboJ , WahnV . Influence of high dosage immuno‐globulin therapy on hyperbilirubinemia in rhesus‐hemolytic disease. A cooperative study [Kooperative Studie zum Einfluß einer hochdosierten Immunglobulintherapie auf die Hyperbilirubinämie bei Rhesusinkompatibilität]. Monatsschrift fur Kinderheilkunde1996;144:516‐9. ">Rübo 1996</a>; <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0014" title="HuangWM , ChenHW , LiN , YangM , JiaoPY . Clinical study of early interventions for ABO hemolytic disease of the newborn. Nan Fang Yi Ke da Xue Xue Bao [Journal of Southern Medical University]2006;26(9):1350‐1. ">Huang 2006</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0013" title="HematyarM , ZareianM . The effects of intravenous immunoglobulin(IVIG) in hemolytic jaundice of the newborn due to ABO and Rh isoimmunization. Acta Paediatrica2011;100(Suppl 463):13‐83. ">Hematyar 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>) (including contact for the previous review) ) in order to obtain additional data or to assist with the determination to include or exclude the study. </p> </section> </section> </section> <section id="CD003313-sec-0061"> <h3 class="title">Risk of bias in included studies</h3> <p>For details of risk of bias of included studies, see the <a href="./references#CD003313-sec-0099" title="">Characteristics of included studies</a> table and <a href="#CD003313-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD003313-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD003313-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD003313-sec-0062"> <h4 class="title">Allocation</h4> <p>Only five studies reported an adequate method of randomization (<a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a> and <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a> provided information on randomization method only through correspondence. One quasi‐randomized controlled trial allocated participants by order of admission (<a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>). This study was rated as high risk of bias for both random sequence generation and allocation concealment. <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a> did not state what method of randomisation was used either in the paper or in response to a query from the review authors, commenting only that that the group allocation was decided by attending neonatologists who differed from those who were conducting the study, which we construed to mean that the allocation was not random, and that the allocation was at high risk of bias. <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a> and <a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a> stated that babies were randomly assigned to treatment groups but did not provide any detail about the method used and the allocation was therefore considered at unclear risk of bias. </p> </section> <section id="CD003313-sec-0063"> <h4 class="title">Blinding</h4> <p>Only two studies used a placebo in the control group (<a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>), and were therefore rated as low risk for performance bias and detection bias. After correspondence with the authors of two additional studies, the risk of detection bias was rated as low; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a> explained that data were kept and entered to their database by personnel who were not involved in the management of the cases and <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a> explained that the person who performed the randomization was different from the one who conducted the study and the one who analyzed the data. None of the other studies described any method of blinding of intervention after allocation and, therefore, they were rated as high risk of bias on both items. </p> </section> <section id="CD003313-sec-0064"> <h4 class="title">Incomplete outcome data</h4> <p>Reporting of outcome data was at low risk of bias in seven studies (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). For six of these studies, there were no missing data. In <a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>, the amount of and reasons for missing data were similar between groups (low risk). One study was at high risk of bias because of a substantial amount of missing data on bilirubin levels (<a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>). </p> </section> <section id="CD003313-sec-0065"> <h4 class="title">Selective reporting</h4> <p>Reporting bias was suspected in four studies because important outcomes were either not reported or were not reported in a form that was useable for meta‐analysis, or that allowed judgment about local treatment practices (e.g. if the authors only stated that there was no significant difference between groups) (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>). The remaining studies were at low risk of bias. </p> </section> <section id="CD003313-sec-0066"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a> had non‐random cross‐over after randomization and another study used an additional criterion for ET in the control group only (<a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>). These two studies were at high risk of bias. <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a> used post‐randomization consent and although follow‐up was complete for all infants for whom consent was obtained, four infants (two randomized to each arm of the study) were excluded because consent was withheld. Two infants were also excluded post‐randomization in one other study because of "protocol violations" but no details were given (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>). The latter two studies were rated at unclear risk of bias because the review authors were unable to assess the impact of these withdrawals on overall outcomes. Three other studies were rated as unclear risk of bias (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>), or low risk of bias (<a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>) for a potential risk of bias. For details see 'Risk of bias' tables. </p> </section> </section> <section id="CD003313-sec-0067"> <h3 class="title" id="CD003313-sec-0067">Effects of interventions</h3> <p>See: <a href="./full#CD003313-tbl-0001"><b>Summary of findings for the main comparison</b> Intravenous immunoglobulin plus phototherapy compared to phototherapy alone for alloimmune hemolytic disease in neonates</a> </p> <section id="CD003313-sec-0068"> <h4 class="title">Intravenous immunoglobulin plus phototherapy versus control (phototherapy only)</h4> <section id="CD003313-sec-0069"> <h5 class="title">Primary outcomes</h5> <section id="CD003313-sec-0070"> <h6 class="title">Exchange transfusion</h6> <p>The results of nine included studies could be entered into the meta‐analysis (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). Most studies found a statistically significant reduction in the use of ET for IVIg treated infants (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>). Two studies concluded that the use of (one or more) ETs was not reduced despite using early IVIg in combination with phototherapy (<a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). The meta‐analysis of all nine studies (658 participants) showed that IVIg reduced the need for an ET (typical RR 0.35, 95% CI 0.25 to 0.49; typical RD ‐0.22, 95% CI ‐0.27 to ‐0.16; NNTB 5) (<a href="./references#CD003313-fig-0003" title="">Analysis 1.1</a>). However, overall, we rated this as very low quality evidence, because, although it was derived from randomized trials, there was very serious risk of bias in most trials, and moderate heterogeneity and serious indirectness, related to the fact that some trials did not use intensive phototherapy, which would be considered standard practice. </p> <p>Subgroup analysis of infants with only Rh incompatibility supported a reduction in the use of ET with IVIg treatment (371 participants, typical RR 0.38, 95% CI 0.25 to 0.58; NNTB 5) (<a href="./references#CD003313-fig-0011" title="">Analysis 2.1</a>) (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). </p> <p>In only those infants born at 37 weeks of gestation or greater, IVIg reduced the use of ETs (391 participants, typical RR 0.39, 95% CI 0.25 to 0.61; NNTB 6) (<a href="./references#CD003313-fig-0039" title="">Analysis 6.1</a>) (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>). In the subgroup of infants born at less than 37 weeks of gestation, IVIg did not reduce the use of ETs (82 participants, typical RR 0.77, 95% CI 0.31 to 1.91; NNTB 20) (data not shown) (<a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). </p> <p>Five studies found reductions in the use of ET where IVIg was used 12 hours or less after birth (335 participants, typical RR 0.41, 95% CI 0.26 to 0.66; NNTB 6) (<a href="./references#CD003313-fig-0019" title="">Analysis 3.1</a>) (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). Reductions were also found in the three studies which used IVIg more than 12 hours after birth (211 participants, typical RR 0.31, 95% CI 0.18 to 0.53; NNTB 4) (data not shown) (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>). Subgroup analyses of infants receiving a single dose of IVIg and infants receiving multiples doses of IVIg supported a reduction in the use of ET with IVIg treatment, although there was insufficient evidence to support a dose‐response effect (single dose of IVIg: 563 participants, typical RR 0.37, 95% CI 0.26 to 0.53; NNTB 6; <a href="./references#CD003313-fig-0027" title="">Analysis 4.1</a> (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>); multiple doses of IVIg: 34 participants, RR 0.27, 95% CI 0.09 to 0.81; NNTB 1; <a href="./references#CD003313-fig-0035" title="">Analysis 5.1</a> (<a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>)). </p> <p>However, despite these apparently promising results, analysis of the only two placebo‐controlled studies at low risk of all forms of bias showed no reduction in the use of ET (172 participants, typical RR 0.98, 95% CI 0.48 to 1.98) (<a href="./references#CD003313-fig-0003" title="">Analysis 1.1</a>.2) (<a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). Furthermore, when all studies were considered, heterogeneity was moderate for use of ET (Chi<sup>2</sup> = 11.32, degrees of freedom (df) = 8 (P = 0.18); I<sup>2</sup> = 29%) and was high for ETs per infant (Tau<sup>2</sup> = 0.04; Chi<sup>2</sup> = 36.77, df = 8 (P &lt; 0.0001); I<sup>2</sup> = 78%), whereas the results of both these outcomes for the placebo‐controlled trials were highly consistent (I<sup>2</sup> = 0% for both). We rated the quality of evidence from the two placebo‐controlled studies as moderate, downgrading it only for imprecision because of the low total number of participants. </p> <p>Overall, immunoglobulin treatment also led to a reduction in the mean number of ETs per infant (658 participants, MD ‐0.34, 95% CI ‐0.50 to ‐0.17). We assessed the level of evidence from the whole group of studies as very low, again downgrading the evidence from randomized trials because of very serious risk of bias, high heterogeneity, indirectness and imprecision. In contrast, analysis of the two placebo‐controlled studies were consistent with each other and when considered alone, yielded moderate quality of evidence that IVIg did not reduce the number of ETs (172 participants, MD ‐0.04, 95% CI ‐0.18 to 0.10) (<a href="./references#CD003313-fig-0004" title="">Analysis 1.2</a>.2). </p> </section> </section> <section id="CD003313-sec-0071"> <h5 class="title">Secondary outcomes</h5> <section id="CD003313-sec-0072"> <h6 class="title">Top‐up transfusions during and after the first week</h6> <p>The results of four studies could be entered in the meta‐analysis of the use of top‐up transfusions in the first week of life (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>) and of seven studies for the use of top‐up transfusions after the first week of life (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). IVIg did not increase the need for top‐up transfusions during the first week (378 participants, typical RR 1.05, 95% CI 0.65 to 1.69) (<a href="./references#CD003313-fig-0005" title="">Analysis 1.3</a>) or in the period after the first week (507 participants, typical RR 1.16, 95% CI 0.97 to 1.38) (<a href="./references#CD003313-fig-0007" title="">Analysis 1.5</a>). IVIg also did not increase the need for top‐up transfusions in the first week and after the first week of life in the following subgroups: infants with Rh incompatibility only (first week: typical RR 1.08, 95% CI 0.65 to 1.77 (<a href="./references#CD003313-fig-0013" title="">Analysis 2.3</a>); after first week: typical RR 1.09, 95% CI 0.92 to 1.28 (<a href="./references#CD003313-fig-0015" title="">Analysis 2.5</a>)); infants born 37 weeks or more of gestation (first week: typical RR 0.91, 95% CI 0.48 to 1.74 (<a href="./references#CD003313-fig-0041" title="">Analysis 6.3</a>); after first week: typical RR 1.18, 95% CI 0.81 to 1.71 (<a href="./references#CD003313-fig-0043" title="">Analysis 6.5</a>)); infants born less than 37 weeks of gestation (first week: typical RR 1.39, 95% CI 0.70 to 2.73; after first week: typical RR 1.24, 95% CI 0.93 to 1.67 (data not shown)); infants treated with IVIg 12 hours or less after birth (first week: typical RR 1.18, 95% CI 0.70 to 2.00 (<a href="./references#CD003313-fig-0021" title="">Analysis 3.3</a>); after first week: typical RR 1.04, 95% CI 0.89 to 1.22 (<a href="./references#CD003313-fig-0023" title="">Analysis 3.5</a>)); and in infants treated with a single dose of IVIg (first week: typical RR 1.05, 95% CI 0.65 to 1.69 (<a href="./references#CD003313-fig-0029" title="">Analysis 4.3</a>); after first week: typical RR 1.13, 95% CI 0.95 to 1.33 (<a href="./references#CD003313-fig-0031" title="">Analysis 4.5</a>)). Although the need for top‐up transfusions during the first week of life was not increased for the subgroup of infants treated with IVIg more than 12 hours after birth (typical RR 0.71, 95% CI 0.24 to 2.12) (data not shown), the need for top‐up transfusions after the first week of life was increased with late IVIg treatment (typical RR 8.00, 95% CI 1.03 to 62.26) (data not shown). However, the CIs were very large and the lower CI limit was nearly one. For infants treated with multiple IVIg doses, the use of top‐up transfusions after the first week of life was not increased (typical RR 5.65, 95% CI 0.25 to 126.87) (<a href="./references#CD003313-fig-0037" title="">Analysis 5.3</a>) and not estimable for the first week of life. </p> <p>For the subgroup of infants included in placebo‐controlled studies only, at low risk of all forms of bias, the need for top‐up transfusions in the first week of life and thereafter was also not altered in infants treated with IVIg (first week: 172 participants, typical RR 1.18, 95% CI 0.70 to 2.00 (<a href="./references#CD003313-fig-0005" title="">Analysis 1.3</a>.2); after first week: typical RR 1.01, 95% CI 0.80 to 1.27 (<a href="./references#CD003313-fig-0007" title="">Analysis 1.5</a>.2)) (<a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). </p> <p><a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a> and <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a> were the only studies included in the analysis of the number of top‐up transfusions per infant. In the first week of life and thereafter, the number of top‐up transfusions was not altered in IVIg treated infants (first week: MD 0.05, 95% CI ‐0.07 to 0.17 (<a href="./references#CD003313-fig-0006" title="">Analysis 1.4</a>); after first week: MD ‐0.00, 95% CI ‐0.12 to 0.12 (<a href="./references#CD003313-fig-0008" title="">Analysis 1.6</a>)). </p> <p>When all studies reporting these outcomes were considered, there was low to very low quality evidence (downgraded for risk of serious to very serious bias, and serious imprecision) that IVIg did not alter the risk of early or late top‐up transfusion. These results were consistent with the findings of the placebo‐controlled trials. </p> </section> <section id="CD003313-sec-0073"> <h6 class="title">Maximum total serum bilirubin</h6> <p>Six studies reported results for maximum serum bilirubin (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). The meta‐analysis of all six studies showed that the mean maximum serum bilirubin decreased by 25.39 µmol/L in infants receiving IVIg (MD ‐25.39 µmol/L, 95% CI ‐34.07 to ‐16.70) (<a href="./references#CD003313-fig-0009" title="">Analysis 1.7</a>). Furthermore, subgroup analyses showed that IVIg decreased maximum bilirubin levels in infants with Rh incompatibility, infants of more than 37 weeks of gestation, infants treated early or late, and infants treated with a single dose of IVIg. However, subgroup analyses of the only two placebo‐controlled studies (<a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>) and of infants born at less than 37 weeks of gestation (<a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>) showed that IVIg did not reduce maximum serum bilirubin (placebo‐controlled trials: MD 0.93 µmol/L, 95% CI ‐23.94 to 25.79 (<a href="./references#CD003313-fig-0009" title="">Analysis 1.7</a>.2); infants born at less than 37 weeks of gestation: MD ‐18.91 µmol/L, 95% CI ‐54.49 to 16.68 (data not shown)). The quality of evidence regarding maximum serum bilirubin was very low, with evidence from six randomized controlled trials downgraded for risk of bias and serious inconsistency; (heterogeneity: Chi<sup>2</sup> = 14.82, df = 5 (P = 0.01); I<sup>2</sup> = 66%). Of note, the peak serum bilirubin in the control groups varied nearly two‐fold between studies, indicating that there were likely to be very different thresholds for ET between the studies. </p> </section> <section id="CD003313-sec-0074"> <h6 class="title">Duration of phototherapy</h6> <p>Results of seven studies could be included in the meta‐analysis of the duration of phototherapy (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). Although all studies gave criteria for commencing phototherapy, only five studies described or provided predefined criteria for ceasing phototherapy (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). Analysis of all seven studies showed that duration of phototherapy decreased by 0.98 days with IVIg treatment (MD ‐0.98 days, 95% CI ‐1.31 to ‐0.66) (<a href="./references#CD003313-fig-0010" title="">Analysis 1.8</a>). All subgroup analyses showed a decrease in duration of phototherapy in IVIg‐treated infants varying from a mean decrease of 1.12 days in infants treated with a single dose of IVIg (MD ‐1.12 days, 95% CI ‐1.30 to ‐0.94) (<a href="./references#CD003313-fig-0034" title="">Analysis 4.8</a>) to 1.24 days in infants treated with IVIg 12 hours or less after birth (MD ‐1.24 days, 95% CI ‐1.44 to ‐1.03 (<a href="./references#CD003313-fig-0026" title="">Analysis 3.8</a>)). However, as for maximum bilirubin levels, analyses of the two placebo‐controlled studies and of infants born less than 37 weeks of gestation showed no reduction in duration of phototherapy (placebo‐controlled trials: MD ‐0.50 days, 95% CI ‐1.24 to 0.24 (<a href="./references#CD003313-fig-0010" title="">Analysis 1.8</a>.2); infants born less than 37 weeks of gestation: MD ‐0.91 days, 95% CI ‐1.96 to 0.14) (data not shown)). </p> </section> <section id="CD003313-sec-0075"> <h6 class="title">Duration of hospitalization</h6> <p>Results of six studies could be entered in the meta‐analysis (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). None of these studies described predefined criteria for hospital discharge and only two studies provided them through correspondence (<a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). The analysis showed that IVIg treatment shortened duration of hospitalization by 1.34 days (MD ‐1.34 days, 95% CI ‐1.60 to ‐1.09) (data not shown). All subgroup analyses showed a shorter duration of hospitalization with IVIg treatment (data not shown). </p> </section> <section id="CD003313-sec-0076"> <h6 class="title">Incidence of adverse reactions</h6> <p>All studies reported or subsequently provided data on adverse reactions, although for most of the trials, we did not know any details of what protocols were used to identify adverse events or how they were defined. Nine studies reported that there were no adverse reactions of IVIg treatment (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0009" title="TanyerG , ŞiklarZ , DallarY , YildirmakY , TiraşÜ . Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Pediatrics2001;47(1):50‐3. ">Tanyer 2001</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0003" title="ElalfyMS , ElbarbaryNS , AbazaHW . Early intravenous immunoglobulin (two‐dose regimen) in the management of severe Rh hemolytic disease of newborn ‐ a prospective randomized controlled trial. European Journal of Pediatrics2011;170(4):461‐7. ">Elalfy 2011</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). None of the adverse reactions were necrotizing enterocolitis. In the study by <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>, two control infants receiving ET developed hypoglycemia and hypocalcemia after ET. In the study by <a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>, one control infant who required ET developed sepsis and one control infant who required ET developed inspissated bile syndrome. However, the authors stated that a causal relationship with ET could not be established in either infant. In the study by <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>, one control infant developed inspissated bile syndrome. <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a> described that "no immediate adverse effects related to IVIg were noted, including fever, allergic reactions, volume overload or hemolysis;" however, they also stated that "ten of the babies who had ET, from both groups, had to be treated for blood culture‐positive or clinical sepsis." In the study by <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a> one infant from the IVIg group developed a <i>Bacillus cereus</i> sepsis with brain abscesses a few days after ET. Sterility tests on the used IVIg batches and cultures of all donor blood products used for intrauterine transfer (IUT) and ET were sterile. The sepsis may have been related to the umbilical venous catheterization and ET. A case report provided information on this exceptional case (<a href="./references#CD003313-bbs2-0062" title="Smits‐WintjensVEHJ , SteggerdaSJ , OepkesD , VanKampIL , KramerCM , WaltherFJ , et al. Bacillus cereus cerebral abscesses in a term neonate with Rhesus hemolytic disease treated with exchange transfusion. Journal of Pediatric Infectious Diseases2010;5(3):277‐80. ">Smits‐Wintjens 2010</a>). </p> <section id="CD003313-sec-0077"> <p><b>Long‐term outcomes</b></p> <p>Only two studies had a relatively long follow‐up period of one year (<a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>) and two years (<a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>). In both studies, there were no cases of kernicterus, deafness or cerebral palsy. All participants of the <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a> study were included in a subsequent long‐term follow‐up study and neurodevelopmental outcome in children of at least two years of age was equal in children treated with IVIg and children treated with placebo (<a href="./references#CD003313-bbs2-0067" title="vanKlinkJM , vanVeenSJ , Smits‐WintjensVE , LindenburgIT , RijkenM , OepkesD , et al. Immunoglobulins in neonates with Rhesus hemolytic disease of the fetus and newborn: long‐term outcome in a randomized trial. Fetal Diagnosis and Therapy2016;39(3):209‐13. ">van Klink 2016</a>). The authors stated that their findings may have been limited by a small sample size. </p> </section> </section> <section id="CD003313-sec-0078"> <h6 class="title">Neonatal mortality</h6> <p>None of the studies reported neonatal mortality data.</p> </section> <section id="CD003313-sec-0079"> <h6 class="title">Incidence of adverse reactions possibly related to the use of intravenous immunoglobulin or exchange transfusion </h6> <p>None of the studies reported Incidence of adverse reactions possibly related to the use of IVIg or ET. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003313-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003313-sec-0080"></div> <section id="CD003313-sec-0081"> <h3 class="title" id="CD003313-sec-0081">Summary of main results</h3> <p>Data from nine studies with 658 participants provided limited evidence that IVIg treatment in neonates with alloimmune HDN reduced the need for ET. Although this review update showed a significant reduction in the need for ET, most of the included studies were at high risk of bias. IVIg treatment was also associated with a significant reduction in maximum bilirubin level and duration of phototherapy when all included studies were analyzed and for most of the subgroup analyses based on type of alloimmunization, gestational age at birth, and timing and number of doses of IVIg. Duration of hospitalization was significantly reduced when analyzing all studies that reported this outcome and for almost all subgroup analyses, including the analysis of studies at low risk of bias only. Although there was some evidence that IVIg reduced hemolysis and shortened hospital stay, these results should be interpreted with considerable caution because the studies reporting these benefits were not blinded, only two studies used predefined criteria for hospital discharge, and criteria for stopping phototherapy were not reported in most studies. In addition, since the late 1980s, guidelines for phototherapy have recommended using it more promptly for infants at risk of hemolysis (<a href="./references#CD003313-bbs2-0032" title="GartnerLM . Disorders of bilirubin metabolism. In: NathanDG , OskiFA editor(s). Hematology of Infancy and Childhood. 3rd Edition. Philadelphia (PA): Saunders, 1987:92. ">Gartner 1987</a>). In many hospitals, the quality of phototherapy has also improved over the years. Nevertheless, the quality/intensity of phototherapy can still vary today, especially in low‐resource settings and if good quality control is not applied. The incidence of late top‐up transfusions is an important outcome, especially in areas where follow‐up of infants is difficult or where supply of safe blood for transfusion is limited. However, as thresholds for top‐up transfusions in neonates vary widely, this outcome is susceptible to bias, particularly in unblinded studies. Seven of nine studies were included in the analysis of the incidence of top‐up transfusion after the first week of life (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). However, only five of the seven studies used predefined criteria for top‐up transfusions (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>; <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). In addition, the predefined criteria varied between studies, thus conclusions were limited. Data on adverse events of IVIg seemed to indicate that it can be used safely. Although we found reports of a higher incidence of NEC in infants with HDN treated with IVIg in the literature (<a href="./references#CD003313-bbs2-0027" title="CorvagliaL , LegnaniE , GallettiS , ArcuriS , AcetiA , FaldellaG . Intravenous immunoglobulin to treat neonatal alloimmune haemolytic disease. Journal of Maternal‐fetal &amp; Neonatal Medicine2012;25(12):2782‐5. ">Corvaglia 2012</a>; <a href="./references#CD003313-bbs2-0030" title="Figueras‐AloyJ , Rodríguez‐MiguélezJM , Iriondo‐SanzM , Salvia‐RoigesMD , Botet‐MussonsF , Carbonell‐EstranyX . Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease. Pediatrics2010;125(1):139‐44. ">Figueras‐Aloy 2010</a>; <a href="./references#CD003313-bbs2-0069" title="YangY , PanJJ , ZhouXG , ZhouXY , ChengR , HuYH . The effect of immunoglobulin treatment for hemolysis on the incidence of necrotizing enterocolitis ‐ a meta‐analysis. European Review for Medical and Pharmacological Sciences2016;20(18):3902‐10. ">Yang 2016</a>), there were no cases of NEC in the current meta‐analysis. </p> <p>Importantly however, subgroup analysis of the only two studies that were placebo‐controlled, blinded, at low risk of all forms of bias, including 172 participants, were very consistent with each other and showed that IVIg treatment had no effect on the need for ET or the number of ETs per infant (<a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). As for ET, analysis of these two studies at low risk of bias demonstrated no difference in maximum bilirubin level and duration of phototherapy. </p> </section> <section id="CD003313-sec-0082"> <h3 class="title" id="CD003313-sec-0082">Overall completeness and applicability of evidence</h3> <p>This review included all (quasi‐) randomized controlled trials on the use of IVIg in alloimmune HDN. We identified 27 trials, of which nine trials, comprising 658 infants, fulfilled inclusion criteria for the review. The only two included studies that were placebo‐controlled comprising a total of 172 infants, enrolled only infants with Rh HDN and the intervention consisted of a single dose of 0.5 g/kg to 0.75 g/kg IVIg administered within four to six hours after birth (<a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a>; <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>). <a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a> included infants of 32 gestational weeks or greater and <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a> included infants of 35 gestational weeks or greater. Criteria for phototherapy and ET were similar in both studies. Evidence from subgroup analysis of these two studies with 172 participants showed that early administration of IVIg in a single dose of 0.5 g/kg to 0.75 g/kg did not reduce ETs or had other benefits in the treatment of Rh HDN. There was no clear evidence from this review that a higher dose improved efficacy. The only randomized controlled trial comparing the effect of two doses of IVIg in Rh HDN showed that 0.5 g/kg and 1 g/kg had a similar effect on the duration of phototherapy, duration of hospitalization and ET requirements (<a href="./references#CD003313-bbs2-0012" title="GirishG , ChawlaD , AgarwalR , PaulVK , DeorariAK . Efficacy of two dose regimen of intravenous immunoglobulin in Rh hemolytic disease of newborn ‐ a randomized controlled trial. Indian Pediatrics2008;45(8):653‐9. ">Girish 2008</a>). However, this study was not powered to detect a difference in the need for ET. Only two studies examined long‐term neurodevelopmental outcome, which found no cases of kernicterus, deafness or cerebral palsy in a follow‐up period of one year (<a href="./references#CD003313-bbs2-0007" title="SantosMC , SáC , GomesSCJr , CamachoLA , MoreiraME . The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double‐blind trial. Transfusion2013;53(4):777‐82. ">Santos 2013</a>) and two years (<a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>). All participants of the <a href="./references#CD003313-bbs2-0008" title="Smits‐WintjensVE , WaltherFJ , RathME , LindenburgIT , tePasAB , KramerCM , et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics2011;127(4):680‐6. ">Smits‐Wintjens 2011</a> study were included in a subsequent long‐term follow‐up study and neurodevelopmental outcome in children of at least two years of age was equal in children treated with IVIg and children treated with placebo (<a href="./references#CD003313-bbs2-0067" title="vanKlinkJM , vanVeenSJ , Smits‐WintjensVE , LindenburgIT , RijkenM , OepkesD , et al. Immunoglobulins in neonates with Rhesus hemolytic disease of the fetus and newborn: long‐term outcome in a randomized trial. Fetal Diagnosis and Therapy2016;39(3):209‐13. ">van Klink 2016</a>). </p> <p>American Academy of Pediatrics guidelines of 2004 recommend the administration of 0.5 g/kg to 1 g/kg IVIg in alloimmune HDN if TSB is rising despite intensive phototherapy or if TSB level is within 34 µmol/L to 51 µmol/L (2 to 3 mg/dL) of exchange level (<a href="./references#CD003313-bbs2-0021" title="American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics2004;114(1):297‐316. ">AAP 2004</a>). Based on the results of this review and because IVIg administration is not completely without risks (<a href="./references#CD003313-bbs2-0026" title="CopelanEA , StrohmPL , KennedyMS , TutschkaPJ . Hemolysis following intravenous immune globulin therapy. Transfusion1986;26(5):410‐12. ">Copelan 1986</a>; <a href="./references#CD003313-bbs2-0049" title="MagnyJF , Bremard‐OuryC , BraultD , MenguyC , VoyerM , LandaisP , et al. Intravenous immunoglobulin therapy for prevention of infection in high‐risk premature infants: report of a multicenter, double blind study. Pediatrics1991;88:437‐43. ">Magny 1991</a>; <a href="./references#CD003313-bbs2-0030" title="Figueras‐AloyJ , Rodríguez‐MiguélezJM , Iriondo‐SanzM , Salvia‐RoigesMD , Botet‐MussonsF , Carbonell‐EstranyX . Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease. Pediatrics2010;125(1):139‐44. ">Figueras‐Aloy 2010</a>), and supplies of IVIg are limited, we do not recommend routine use of IVIg. However, since there is some evidence that it reduces hemolysis and it appears safe in infants with alloimmune HDN, it might be reasonable to consider using it in special circumstances, such as during transfer of an infant to a location that can perform an ET, where the risk of ET is considered to be much higher than usual, such as in very or extremely low birth weight infants, or in the context of a future research study. </p> </section> <section id="CD003313-sec-0083"> <h3 class="title" id="CD003313-sec-0083">Quality of the evidence</h3> <p>The quality of included studies ranged from fulfilling none of the 'risk of bias' criteria to fulfilling all criteria (see 'Risk of bias' section of <a href="./references#CD003313-sec-0099" title="">Characteristics of included studies</a> table, and <a href="./full#CD003313-tbl-0001">summary of findings Table for the main comparison</a>). Only two of nine trials fulfilled all criteria to be rated as high‐quality studies. We made the decision to evaluate the quality of evidence using GRADE criteria separately for the seven studies at high risk of bias and the two studies at low risk of bias, because evaluation of the seven studies at high risk of bias as a group also demonstrated other concerns including inconsistency and indirectness. For the outcomes of use and number of ETs in the first week, the quality of evidence from the seven studies at high risk of bias was very low, whereas the evidence from the two studies at low risk of bias was moderate (downgraded only for small number of participants). For the outcome of top‐up transfusions after the first week, we evaluated the level of evidence only for Rh HDN and only for the two studies at low risk of bias, because we deemed this outcome to usually be irrelevant for infants with ABO incompatibility (who are at much lower risk of late anemia) and because of incomplete reporting of data in other studies. The evidence was of very low quality. Analysis of the effect of IVIg on the need for ET in infants with ABO incompatibility included only three studies at high risk of bias (<a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>; <a href="./references#CD003313-bbs2-0004" title="MiqdadAM , AbdelbasitOB , ShaheedMM , SeidahmedMZ , AbomelhaAM , ArcalaOP . Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Journal of Maternal‐fetal &amp; Neonatal Medicine2004;16(3):163‐6. ">Miqdad 2004</a>; <a href="./references#CD003313-bbs2-0005" title="NasseriF , MamouriGA , BabaeiH . Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Medical Journal2006;27(12):1827‐30. ">Nasseri 2006</a>), because other studies only enrolled infants with Rh HDN, did not use predefined criteria for top‐up transfusion or did not provide sufficient detail to separate Rh‐ and ABO‐affected infants. The quality of evidence for IVIg for ABO incompatibility was very low (GRADE analysis not shown). For several of the secondary outcomes of the review, the RR (or other relevant statistic) was not estimable for included studies (no events in either intervention or control groups), highlighting the extent to which these studies were seriously underpowered. In summary, we considered that the evidence from the two trials at low risk of bias provided a sufficient quality of evidence to guide practice. </p> <p>It was unclear why placebo‐controlled, high‐quality trials yielded such different results. Possibilities included that when administration of IVIg was not compared with use of a placebo administered in similar dose and over similar duration, there were differences in timing of the next bilirubin measurement, meaning that in IVIg‐treated infants, there was longer exposure to phototherapy before the decision about ET was made. Another possibility was that there was bias in the decision to perform an ET, influenced by knowledge of group allocation. A third possibility was that rather than a specific immunomodulatory effect, IVIg (and where used, the placebo solution) has a sufficient non‐specific dilutional effect to change the rate of rise of bilirubin, altering duration of exposure to phototherapy and decision making about ET. </p> </section> <section id="CD003313-sec-0084"> <h3 class="title" id="CD003313-sec-0084">Potential biases in the review process</h3> <p>We tried to minimize bias by working with two review authors who independently assessed eligibility for inclusion of trials, extracted data and assessed risk of bias. However, we were aware that these parts of the review process were based on personal judgment because reviewing research is influenced by prior beliefs. In addition, one included trial was performed by two of the five review authors. Nevertheless, we attempted to review all studies in a similar way. In addition, we were unable to contact authors of all potentially eligible studies and, therefore, we could not include all available data. While the translator of the Turkish included study was a medical doctor from Turkish parents, he may have missed some details regarding the risk of bias of that study. </p> </section> <section id="CD003313-sec-0085"> <h3 class="title" id="CD003313-sec-0085">Agreements and disagreements with other studies or reviews</h3> <p>The overall findings of this review were consistent with previous systematic reviews. <a href="./references#CD003313-bbs2-0048" title="LouisD , MoreK , OberoiS , ShahPS . Intravenous immunoglobulin in isoimmune haemolytic disease of newborn: an updated systematic review and meta‐analysis. Archives of Disease in Childhood2014;99(4):F325‐31. ">Louis 2014</a> included 12 studies (813 participants) and concurred with our finding that high‐quality studies found no effect of IVIg, whereas low‐quality studies found IVIg effective in HDN. <a href="./references#CD003313-bbs2-0033" title="GottsteinR , CookeRW . Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Archives of Disease in Childhood. Fetal and Neonatal Edition2003;88(1):F6‐10. ">Gottstein 2003</a> included three studies that were also included in our review (<a href="./references#CD003313-bbs2-0006" title="RüboJ , AlbrechtK , LaschP , LauftkötterE , LeititisJ , MarsanD , et al. High‐dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. Journal of Pediatrics1992;121(1):93‐7. ">Rübo 1992</a>; <a href="./references#CD003313-bbs2-0002" title="DağoğluT , OvaliF , SamanciN , BengisuE . High‐dose intravenous immunoglobulin therapy for rhesus haemolytic disease. Journal of International Medical Research1995;23(4):264‐71. ">Dağoğlu 1995</a>; <a href="./references#CD003313-bbs2-0001" title="AlpayF , SariciSÜ , OkutanV , ErdemG , ÖzcanO , GökçayE . High‐dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatrica1999;88(2):216‐9. ">Alpay 1999</a>), and one study that was excluded from our review (<a href="./references#CD003313-bbs2-0019" title="VotoLS , SexerH , FerreiroG , TavosnanskaJ , OrtiJ , MathetER , et al. Neonatal administration of high‐dose intravenous immunoglobulin in rhesus hemolytic disease. Journal of Perinatal Medicine1995;23(6):443‐51. ">Voto 1995</a>). They concluded that with IVIg treatment significantly fewer infants required ET. Duration of hospitalization and phototherapy were also significantly reduced in their review. However, based on our judgment, none of their included studies was of high quality. Two Chinese systematic reviews (<a href="./references#CD003313-bbs2-0046" title="LiMJ , ChenCH , WuQ , ShiW , YangQ , LiMN . Intravenous immunoglobulin G for hemolytic disease of the newborn: a systematic review. Chinese Journal of Evidence‐Based Medicine2012;10:1199‐204. ">Li 2010a</a>; <a href="./references#CD003313-bbs2-0047" title="LiZH , WangJ , ChenC . Meta analysis of the effect of immunoglobulin infusion on neonatal isoimmune hemolytic disease caused by blood group incompatibility. Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics2010;48(9):656‐60. ">Li 2010b</a>) also found a reduction in ET requirements, duration of phototherapy and hospitalization but concluded that well‐designed trials with a larger sample size were required for further evaluation of the efficacy and safety of IVIg. Until the date we conducted our search, our review was the most recent, extensive and up‐to‐date review of all randomized and quasi‐randomized trials on the effect of IVIg in alloimmune HDN. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003313-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram of study selection process. IVIg: intravenous immunoglobulin; RCT: randomized controlled trial." data-id="CD003313-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram of study selection process. IVIg: intravenous immunoglobulin; RCT: randomized controlled trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/full#CD003313-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD003313-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/full#CD003313-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome 1 Use of exchange transfusion (≥ 1)." data-id="CD003313-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome 1 Use of exchange transfusion (≥ 1). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome 2 Exchange transfusions per infant, by study quality." data-id="CD003313-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome 2 Exchange transfusions per infant, by study quality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome 3 Use of top‐up transfusion in 1st week by study quality." data-id="CD003313-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome 3 Use of top‐up transfusion in 1st week by study quality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome 4 Top‐up transfusions in 1st week per infant by study quality." data-id="CD003313-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome 4 Top‐up transfusions in 1st week per infant by study quality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome 5 Use of top‐up transfusion after 1st week by study quality." data-id="CD003313-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome 5 Use of top‐up transfusion after 1st week by study quality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome 6 Top‐up transfusions after first week per infant, by study quality." data-id="CD003313-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome 6 Top‐up transfusions after first week per infant, by study quality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome 7 Maximum total serum bilirubin (µmol/L) by study quality." data-id="CD003313-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome 7 Maximum total serum bilirubin (µmol/L) by study quality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome 8 Duration of phototherapy (days) by study quality." data-id="CD003313-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome 8 Duration of phototherapy (days) by study quality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only, Outcome 1 Use of exchange transfusion (≥ 1)." data-id="CD003313-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only, Outcome 1 Use of exchange transfusion (≥ 1). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only, Outcome 2 Exchange transfusions per infant." data-id="CD003313-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only, Outcome 2 Exchange transfusions per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only, Outcome 3 Use top‐up transfusion in 1st week." data-id="CD003313-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only, Outcome 3 Use top‐up transfusion in 1st week. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only, Outcome 4 Top‐up transfusions in 1st week per infant." data-id="CD003313-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only, Outcome 4 Top‐up transfusions in 1st week per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only, Outcome 5 Use of top‐up transfusion after 1st week." data-id="CD003313-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only, Outcome 5 Use of top‐up transfusion after 1st week. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only, Outcome 6 Top‐up transfusions after 1st week per infant." data-id="CD003313-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only, Outcome 6 Top‐up transfusions after 1st week per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only, Outcome 7 Maximum total serum bilirubin (µmol/L)." data-id="CD003313-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only, Outcome 7 Maximum total serum bilirubin (µmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only, Outcome 8 Duration of phototherapy (days)." data-id="CD003313-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only, Outcome 8 Duration of phototherapy (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth, Outcome 1 Use of exchange transfusion (≥ 1)." data-id="CD003313-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth, Outcome 1 Use of exchange transfusion (≥ 1). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth, Outcome 2 Exchange transfusions per infant." data-id="CD003313-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth, Outcome 2 Exchange transfusions per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth, Outcome 3 Use of top‐up transfusion in 1st week." data-id="CD003313-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth, Outcome 3 Use of top‐up transfusion in 1st week. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth, Outcome 4 Top‐up transfusions in 1st week per infant." data-id="CD003313-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth, Outcome 4 Top‐up transfusions in 1st week per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth, Outcome 5 Use of top‐up transfusions after 1st week." data-id="CD003313-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth, Outcome 5 Use of top‐up transfusions after 1st week. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth, Outcome 6 Top‐up transfusions after 1st week per infant." data-id="CD003313-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth, Outcome 6 Top‐up transfusions after 1st week per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth, Outcome 7 Maximum total serum bilirubin (µmol/L)." data-id="CD003313-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth, Outcome 7 Maximum total serum bilirubin (µmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth, Outcome 8 Duration of phototherapy (days)." data-id="CD003313-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth, Outcome 8 Duration of phototherapy (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg, Outcome 1 Use of exchange transfusion (≥ 1)." data-id="CD003313-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg, Outcome 1 Use of exchange transfusion (≥ 1). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg, Outcome 2 Exchange transfusions per infant." data-id="CD003313-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg, Outcome 2 Exchange transfusions per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg, Outcome 3 Use of top‐up transfusions in 1st week." data-id="CD003313-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg, Outcome 3 Use of top‐up transfusions in 1st week. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg, Outcome 4 Top‐up transfusions in 1st week per infant." data-id="CD003313-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg, Outcome 4 Top‐up transfusions in 1st week per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg, Outcome 5 Use of top‐up transfusion after 1st week." data-id="CD003313-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg, Outcome 5 Use of top‐up transfusion after 1st week. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg, Outcome 6 Top‐up transfusions after 1st week per infant." data-id="CD003313-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg, Outcome 6 Top‐up transfusions after 1st week per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg, Outcome 7 Maximum total serum bilirubin (µmol/L)." data-id="CD003313-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg, Outcome 7 Maximum total serum bilirubin (µmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg, Outcome 8 Duration of phototherapy (days)." data-id="CD003313-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg, Outcome 8 Duration of phototherapy (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Multiple doses of IVIg, Outcome 1 Use of exchange transfusion (≥ 1)." data-id="CD003313-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Multiple doses of IVIg, Outcome 1 Use of exchange transfusion (≥ 1). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Multiple doses of IVIg, Outcome 2 Exchange transfusions per infant." data-id="CD003313-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Multiple doses of IVIg, Outcome 2 Exchange transfusions per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Multiple doses of IVIg, Outcome 3 Use of top‐up transfusions after 1st week." data-id="CD003313-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Multiple doses of IVIg, Outcome 3 Use of top‐up transfusions after 1st week. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Multiple doses of IVIg, Outcome 4 Duration of phototherapy (days)." data-id="CD003313-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Multiple doses of IVIg, Outcome 4 Duration of phototherapy (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 1 Use of exchange transfusion (≥ 1)." data-id="CD003313-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 1 Use of exchange transfusion (≥ 1). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 2 Exchange transfusions per infant." data-id="CD003313-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 2 Exchange transfusions per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 3 Use of top‐up transfusion in 1st week." data-id="CD003313-fig-0041" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 3 Use of top‐up transfusion in 1st week. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 4 Top‐up transfusions in 1st week per infant." data-id="CD003313-fig-0042" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 4 Top‐up transfusions in 1st week per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 5 Use of top‐up transfusion after 1st week." data-id="CD003313-fig-0043" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 5 Use of top‐up transfusion after 1st week. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 6 Top‐up transfusions after 1st week per infant." data-id="CD003313-fig-0044" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 6 Top‐up transfusions after 1st week per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 7 Maximum total serum bilirubin (µmol/L)." data-id="CD003313-fig-0045" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 7 Maximum total serum bilirubin (µmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 8 Duration of phototherapy (days)." data-id="CD003313-fig-0046" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 8 Duration of phototherapy (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003313-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/urn:x-wiley:14651858:media:CD003313:CD003313-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_t/tCD003313-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 9 Duration of hospitalization (days)." data-id="CD003313-fig-0047" src="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks, Outcome 9 Duration of hospitalization (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/media/CDSR/CD003313/image_n/nCD003313-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003313-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intravenous immunoglobulin plus phototherapy compared to phototherapy alone for alloimmune hemolytic disease in neonates</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intravenous immunoglobulin plus phototherapy compared to phototherapy alone for alloimmune hemolytic disease in neonates</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> neonates with alloimmune hemolytic disease </p> <p><b>Settings:</b> ‐ </p> <p><b>Intervention:</b> IVIg + phototherapy </p> <p><b>Comparison:</b> phototherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with phototherapy alone</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with IVIg + phototherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Use of ET</b> (≥ 1); all studies </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>658<br/> (9 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.35</b><br/> (0.25 to 0.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>329 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214 fewer per 1000<br/> (247 fewer to 168 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Use of ET</b> (≥ 1); placebo‐controlled studies </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>172<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.98</b><br/> (0.48 to 1.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 fewer per 1000<br/> (80 fewer to 150 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ETs performed per infant</b>; all studies </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>658<br/> (9 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean ETs per infant for all studies was 0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.34 lower<br/> (0.5 lower to 0.17 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ETs performed per infant</b>; placebo‐controlled studies </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>172<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean ETs per infant for placebo‐controlled studies was 0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.04 lower<br/> (0.18 lower to 0.1 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Use of top‐up transfusion in 1st week of life</b>; all studies </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>378<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.05</b><br/> (0.65 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 more per 1000<br/> (45 fewer to 89 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Use of top‐up transfusion after 1st week of life</b>; all studies </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>507<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.16</b><br/> (0.97 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 more per 1000<br/> (7 fewer to 83 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Maximum total serum bilirubin</b> (µmol/L); all studies </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>451<br/> (6 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>10,11,12</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean maximum serum bilirubin (µmol/L) for all studies was 0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 25.39 lower<br/> (34.07 lower to 16.7 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>ET:</b> exchange transfusion; <b>IVIg:</b> intravenous immunoglobulin; <b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> quality<b>:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate</b> quality<b>:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low</b> quality<b>:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low</b> quality<b>:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>In three studies, the method of randomization was not stated and there was inadequate concealment of random sequence (selection bias). In seven studies, there was no blinding of personnel (performance bias) and in five studies, no blinding of outcome assessment (detection bias). Among other potential sources of bias were that mean bilirubin levels at study entry were already higher than the threshold for the outcome (ET) in one study, differences between study groups despite randomization (one study), postrandomization withdrawals or cross‐over between study groups (two studies) and criteria for ET differing between treatment arms (one study). </p> <p><sup>2</sup>Substantial heterogeneity: Chi<sup>2</sup> = 34.63, df = 8 (P = 0.0003), I<sup>2</sup> = 77%. </p> <p><sup>3</sup>Four studies did not clearly specify use of intensive phototherapy (which should be a routine intervention for infants at high risk of ET). </p> <p><sup>4</sup>Total number of participants in these two trials was low, increasing the risk of possible bias. </p> <p><sup>5</sup>Only a few infants needed a second ET. </p> <p><sup>6</sup>In one trial, the methods of randomization and allocation concealment were not stated. In two studies, there was no blinding of personnel (performance bias). </p> <p><sup>7</sup>Combined studies were underpowered for use of top‐up transfusion in 1st week. A total of 378 infants were enrolled in all four trials, and the overall frequency of top‐up transfusion was low (13.8%). </p> <p><sup>8</sup>Substantial heterogeneity: Chi<sup>2</sup> = 15.60, df = 5 (P = 0.008); I<sup>2</sup> = 68%. </p> <p><sup>9</sup>Due to small differences between treatment groups, the combined studies were underpowered for use of top‐up transfusion after 1st week. </p> <p><sup>10</sup>Four studies used no method of blinding the intervention. </p> <p><sup>11</sup>Substantial heterogeneity: Chi<sup>2</sup> = 14.82, df = 5 (P = 0.01); I<sup>2</sup> = 66%. </p> <p><sup>12</sup>Peak serum bilirubin in the control group varied 1.86‐fold between studies; there was considerably greater variation between studies than between groups within studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intravenous immunoglobulin plus phototherapy compared to phototherapy alone for alloimmune hemolytic disease in neonates</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/full#CD003313-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003313-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intravenous immunoglobulin plus phototherapy versus phototherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Use of exchange transfusion (≥ 1) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.25, 0.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.18, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.48, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Exchange transfusions per infant, by study quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.34 [‐0.50, ‐0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐0.64, ‐0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.18, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Use of top‐up transfusion in 1st week by study quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.65, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.24, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.70, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Top‐up transfusions in 1st week per infant by study quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.07, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.07, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Use of top‐up transfusion after 1st week by study quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.97, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.08, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.80, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Top‐up transfusions after first week per infant, by study quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.12, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.12, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Maximum total serum bilirubin (µmol/L) by study quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐25.39 [‐34.07, ‐16.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐29.05 [‐38.32, ‐19.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [‐23.94, 25.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Duration of phototherapy (days) by study quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.98 [‐1.31, ‐0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.06 [‐1.41, ‐0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.24, 0.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intravenous immunoglobulin plus phototherapy versus phototherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003313-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Use of exchange transfusion (≥ 1) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.25, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.13, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.48, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Exchange transfusions per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.34, ‐0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.51, ‐0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.18, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Use top‐up transfusion in 1st week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.65, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.10, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.70, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Top‐up transfusions in 1st week per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.07, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.07, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Use of top‐up transfusion after 1st week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.92, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.96, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.80, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Top‐up transfusions after 1st week per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.12, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Maximum total serum bilirubin (µmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐21.77 [‐30.86, ‐12.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐25.27 [‐35.04, ‐15.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [‐23.94, 25.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Duration of phototherapy (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.23 [‐1.43, ‐1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.28 [‐1.49, ‐1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.24, 0.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Intravenous immunoglobulin plus phototherapy versus phototherapy. Rh incompatibility only</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003313-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Use of exchange transfusion (≥ 1) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.26, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.11, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.48, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Exchange transfusions per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.28, ‐0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.42, ‐0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.18, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Use of top‐up transfusion in 1st week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.70, 2.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Top‐up transfusions in 1st week per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.07, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Use of top‐up transfusions after 1st week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.89, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Top‐up transfusions after 1st week per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.12, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Maximum total serum bilirubin (µmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐20.57 [‐29.81, ‐11.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐24.01 [‐33.96, ‐14.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [‐23.94, 25.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Duration of phototherapy (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.24 [‐1.44, ‐1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐1.51, ‐1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.24, 0.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. IVIg administration ≤ 12 hours after birth</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003313-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Use of exchange transfusion (≥ 1) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.26, 0.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.17, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.48, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Exchange transfusions per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.28, ‐0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.36, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.18, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Use of top‐up transfusions in 1st week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.65, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Top‐up transfusions in 1st week per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.07, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Use of top‐up transfusion after 1st week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.95, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Top‐up transfusions after 1st week per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.12, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Maximum total serum bilirubin (µmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐25.39 [‐34.07, ‐16.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐29.05 [‐38.32, ‐19.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [‐23.94, 25.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Duration of phototherapy (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.12 [‐1.30, ‐0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.16 [‐1.34, ‐0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.24, 0.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Single dose of IVIg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003313-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Multiple doses of IVIg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Use of exchange transfusion (≥ 1) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.09, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Exchange transfusions per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.94 [‐1.45, ‐0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Use of top‐up transfusions after 1st week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.65 [0.25, 126.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Duration of phototherapy (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.47 [‐2.52, ‐0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Multiple doses of IVIg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003313-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Use of exchange transfusion (≥ 1) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.25, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.18, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.49, 6.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Exchange transfusions per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.26, ‐0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.36, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.12, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Use of top‐up transfusion in 1st week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.48, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Top‐up transfusions in 1st week per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.35, 0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Use of top‐up transfusion after 1st week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.81, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Top‐up transfusions after 1st week per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.20, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Maximum total serum bilirubin (µmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐26.81 [‐35.97, ‐17.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐30.33 [‐39.83, ‐20.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.47 [‐15.00, 53.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Duration of phototherapy (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐1.38, ‐1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.25 [‐1.44, ‐1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐0.75, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Duration of hospitalization (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.33 [‐1.59, ‐1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Studies without a placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.37 [‐1.63, ‐1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Placebo‐controlled studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.32 [‐1.69, 1.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Intravenous immunoglobulin (IVIg) plus phototherapy versus phototherapy. Gestational age ≥ 37 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003313.pub2/references#CD003313-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003313.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003313-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003313-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD003313-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003313-note-0007">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003313\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003313\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003313\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003313\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003313\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003313\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003313\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003313\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003313\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003313\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003313\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003313\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003313\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003313\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003313\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003313\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003313\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003313\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003313.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003313.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003313.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003313.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003313.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714769766"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003313.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714769769"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003313.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d76c4590e937d',t:'MTc0MDcxNDc3MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 